Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	B-cell_type
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T-lymphocytes	B-cell_type
.	O

The	O
regulatory	O
role	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
PTPases	B-protein
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	B-protein
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	B-cell_line
human	I-cell_line
leukaemic	I-cell_line
T-cells	I-cell_line
.	O

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
lck	B-protein
and	O
fyn	B-protein
(	O
4-	O
and	O
3-fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
proteins	I-protein
,	O
notably	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B-protein
PTPase	I-protein
and	O
was	O
not	O
observed	O
in	O
CD45-deficient	B-cell_line
variants	I-cell_line
of	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

In	O
the	O
CD45-negative	B-cell_line
variant	I-cell_line
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
and	O
accumulation	O
of	O
its	O
mRNA	B-RNA
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T-lymphocyte	B-cell_type
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	O
antigen	O
and	O
the	O
interleukin	O
2	O
receptor	O
alpha-chain	O
(	O
CD25	O
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T-cell	B-cell_type
antigen	B-protein
receptor	I-protein
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O

Pervanadate	B-protein
activated	I-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA-binding	O
activity	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

We	O
thus	O
conclude	O
that	O
PTPases	B-protein
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	B-cell_type
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

Biochem	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
297	NULL
,	NULL
163-173	NULL
(	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
)	NULL
163	NULL
Induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
T-cell	NULL
activation	NULL
by	NULL
vanadate	NULL
peroxide	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
Véronique	NULL
IMBERT	NULL
,	NULL
Jean-Francois	NULL
PEYRON	NULL
,	NULL
*	NULL
Dariush	NULL
FARAHI	NULL
FAR	NULL
,	NULL
Bernard	NULL
MARI	NULL
,	NULL
Patrick	NULL
AUBERGER	NULL
and	NULL
Bernard	NULL
ROSSI	NULL
INSERM	NULL
U364	NULL
,	NULL
Faculté	NULL
de	NULL
Médecine	NULL
,	NULL
Avenue	NULL
de	NULL
Valombrose	NULL
,	NULL
06107	NULL
Nice	NULL
cedex	NULL
02	NULL
,	NULL
France	NULL
Rapid	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
key	NULL
cellular	NULL
proteins	NULL
is	NULL
a	NULL
crucial	NULL
event	NULL
in	NULL
the	NULL
transduction	NULL
of	NULL
activation	NULL
signals	NULL
to	NULL
T-lymphocytes	NULL
.	NULL

The	NULL
regulatory	NULL
role	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
(	NULL
PTPases	NULL
)	NULL
in	NULL
this	NULL
process	NULL
was	NULL
explored	NULL
by	NULL
studying	NULL
the	NULL
effects	NULL
of	NULL
a	NULL
powerful	NULL
PTPase	NULL
inhibitor	NULL
,	NULL
vanadate	NULL
peroxide	NULL
(	NULL
pervanadate	NULL
)	NULL
,	NULL
on	NULL
the	NULL
activation	NULL
cascade	NULL
of	NULL
Jurkat	NULL
human	NULL
leukaemic	NULL
T-cells	NULL
.	NULL

Pervanadate	NULL
induced	NULL
activation	NULL
of	NULL
the	NULL
tyrosine	NULL
kinases	NULL
Ick	NULL
and	NULL
fyn	NULL
(	NULL
4-	NULL
and	NULL
3-fold	NULL
respectively	NULL
)	NULL
and	NULL
a	NULL
dramatic	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
proteins	NULL
,	NULL
notably	NULL
phospholipase	NULL
C	NULL
yl	NULL
.	NULL

After	NULL
this	NULL
event	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
rise	NULL
in	NULL
intracellular	NULL
Ca**	NULL
concentration	NULL
,	NULL
corresponding	NULL
to	NULL
an	NULL
influx	NULL
.	NULL

This	NULL
effect	NULL
required	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
CD45	NULL
PTPase	NULL
and	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
CD45-deficient	NULL
variants	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
CD4S5-negative	NULL
variant	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
globally	NULL
decreased	NULL
and	NULL
some	NULL
phosphoryl-	NULL
ated	NULL
substrates	NULL
were	NULL
specifically	NULL
missing	NULL
.	NULL

Pervanadate	NULL
also	NULL
stimulated	NULL
transcription	NULL
of	NULL
the	NULL
c-fos	NULL
gene	NULL
and	NULL
accumulation	NULL
of	NULL
its	NULL
mRNA	NULL
as	NULL
well	NULL
as	NULL
several	NULL
other	NULL
hallmarks	NULL
of	NULL
T-lymphocyte	NULL
activation	NULL
such	NULL
as	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
CD69	NULL
antigen	NULL
and	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
a-chain	NULL
(	NULL
CD25	NULL
)	NULL
.	NULL

Pervanadate	NULL
synergized	NULL
with	NULL
signals	NULL
delivered	NULL
by	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
engagement	NULL
or	NULL
by	NULL
a	NULL
phorbol	NULL
ester	NULL
to	NULL
induce	NULL
interleukin	NULL
2	NULL
production	NULL
.	NULL

Pervanadate	NULL
activated	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
DNA-binding	NULL
activity	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
.	NULL

We	NULL
thus	NULL
conclude	NULL
that	NULL
PTPases	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
signal	NULL
transduction	NULL
culminating	NULL
in	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
appears	NULL
sufficient	NULL
per	NULL
se	NULL
to	NULL
initiate	NULL
a	NULL
complete	NULL
activation	NULL
pro-gramme	NULL
.	NULL

INTRODUCTION	NULL
Antigen	NULL
recognition	NULL
by	NULL
T-lymphocytes	NULL
through	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
,	NULL
TcR-CD3	NULL
,	NULL
is	NULL
a	NULL
central	NULL
event	NULL
in	NULL
the	NULL
initiation	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
.	NULL

This	NULL
multimeric	NULL
complex	NULL
consists	NULL
of	NULL
an	NULL
antigen-binding	NULL
clonotypic	NULL
«	NULL
/	NULL
$	NULL
heterodimer	NULL
(	NULL
TcR	NULL
)	NULL
non-covalently	NULL
associated	NULL
with	NULL
the	NULL
invariant	NULL
chains	NULL
of	NULL
the	NULL
CD3	NULL
complex	NULL
y	NULL
,	NULL
8	NULL
and	NULL
e	NULL
and	NULL
the	NULL
disulphide-linked	NULL
homodimer	NULL
&	NULL
-£	NULL
[	NULL
1,2	NULL
]	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
TcR-CD3	NULL
complex	NULL
by	NULL
antigen	NULL
or	NULL
agonistic	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
mAbs	NULL
)	NULL
raised	NULL
against	NULL
TcR	NULL
or	NULL
CD3	NULL
activates	NULL
a	NULL
signal-transduction	NULL
cascade	NULL
.	NULL

The	NULL
earliest	NULL
event	NULL
in	NULL
this	NULL
cascade	NULL
is	NULL
a	NULL
stimulation	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
cellular	NULL
proteins	NULL
[	NULL
3,4	NULL
]	NULL
.	NULL

Tyrosine	NULL
kinase	NULL
(	NULL
PTK	NULL
)	NULL
inhibitors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
block	NULL
early	NULL
as	NULL
well	NULL
as	NULL
late	NULL
events	NULL
resulting	NULL
from	NULL
TcR-CD3	NULL
triggering	NULL
[	NULL
5,6	NULL
]	NULL
,	NULL
suggesting	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
absolutely	NULL
required	NULL
for	NULL
all	NULL
downstream	NULL
events	NULL
in	NULL
the	NULL
T-cell	NULL
response	NULL
to	NULL
antigen	NULL
.	NULL

Moreover	NULL
,	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
leads	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
phospholipase	NULL
Cy1	NULL
(	NULL
PLCy1	NULL
)	NULL
which	NULL
is	NULL
likely	NULL
to	NULL
induce	NULL
an	NULL
augmentation	NULL
of	NULL
its	NULL
catalytic	NULL
activity	NULL
[	NULL
7,8	NULL
]	NULL
and	NULL
the	NULL
subsequent	NULL
generation	NULL
of	NULL
the	NULL
second	NULL
messengers	NULL
inositol	NULL
trisphosphate	NULL
(	NULL
IP	NULL
,	NULL
)	NULL
and	NULL
diacylglycerol	NULL
[	NULL
9	NULL
]	NULL
.	NULL

As	NULL
the	NULL
TcR-CD3	NULL
does	NULL
not	NULL
possess	NULL
intrinsic	NULL
kinase	NULL
activity	NULL
,	NULL
it	NULL
is	NULL
probably	NULL
associated	NULL
with	NULL
independent	NULL
PTK	NULL
(	NULL
s	NULL
)	NULL
.	NULL

Candidates	NULL
for	NULL
this	NULL
role	NULL
are	NULL
fyn	NULL
and	NULL
Ick	NULL
,	NULL
two	NULL
members	NULL
of	NULL
the	NULL
src	NULL
tyrosine	NULL
kinase	NULL
family	NULL
[	NULL
10,11	NULL
]	NULL
.	NULL

Recently	NULL
,	NULL
fyn	NULL
has	NULL
been	NULL
found	NULL
to	NULL
coprecipitate	NULL
with	NULL
the	NULL
CD3	NULL
complex	NULL
[	NULL
12	NULL
]	NULL
and	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
TcR-CD3	NULL
triggering	NULL
[	NULL
13	NULL
]	NULL
.	NULL

Lok	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
CD4	NULL
surface	NULL
molecule	NULL
which	NULL
forms	NULL
a	NULL
co-receptor	NULL
with	NULL
TcR-CD3	NULL
[	NULL
14,15	NULL
]	NULL
.	NULL

Although	NULL
Ick	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
CD4	NULL
signalling	NULL
[	NULL
16	NULL
]	NULL
,	NULL
it	NULL
seems	NULL
to	NULL
be	NULL
also	NULL
required	NULL
for	NULL
normal	NULL
TcR-CD3	NULL
signal	NULL
transduction	NULL
[	NULL
17	NULL
]	NULL
.	NULL

To	NULL
avoid	NULL
prolonged	NULL
stimulation	NULL
of	NULL
the	NULL
cell	NULL
which	NULL
could	NULL
lead	NULL
to	NULL
malignant	NULL
proliferation	NULL
,	NULL
tyrosine	NULL
phosphorylation	NULL
must	NULL
be	NULL
tightly	NULL
controlled	NULL
during	NULL
cell	NULL
homoeostasis	NULL
.	NULL

Protein	NULL
tyrosine	NULL
phosphatases	NULL
(	NULL
PTPases	NULL
)	NULL
specifically	NULL
dephosphorylate	NULL
phosphotyrosine	NULL
residues	NULL
thereby	NULL
negatively	NULL
regulating	NULL
tyrosine	NULL
kinase	NULL
signalling	NULL
[	NULL
18	NULL
]	NULL
.	NULL

In	NULL
T-lymphocytes	NULL
,	NULL
the	NULL
major	NULL
PTPase	NULL
expressed	NULL
on	NULL
the	NULL
plasma	NULL
membrane	NULL
is	NULL
the	NULL
CD45	NULL
antigen	NULL
[	NULL
19	NULL
]	NULL
.	NULL

Studies	NULL
of	NULL
CD45-deficient	NULL
variants	NULL
of	NULL
various	NULL
human	NULL
T-cell	NULL
lines	NULL
showed	NULL
that	NULL
CD45	NULL
is	NULL
required	NULL
to	NULL
couple	NULL
the	NULL
T-cell	NULL
receptor	NULL
to	NULL
downstream	NULL
signalling	NULL
events	NULL
[	NULL
20-22	NULL
]	NULL
.	NULL

Moreover	NULL
,	NULL
anti-CD45	NULL
mAbs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
T-	NULL
and	NULL
B-cell	NULL
activation	NULL
[	NULL
23,24	NULL
]	NULL
.	NULL

T-cells	NULL
also	NULL
express	NULL
at	NULL
least	NULL
another	NULL
PTPase	NULL
,	NULL
Tc	NULL
PTPase	NULL
,	NULL
a	NULL
cytosolic	NULL
enzyme	NULL
of	NULL
as	NULL
yet	NULL
unknown	NULL
function	NULL
[	NULL
25	NULL
]	NULL
.	NULL

To	NULL
study	NULL
the	NULL
role	NULL
of	NULL
PTPases	NULL
during	NULL
T-cell	NULL
activation	NULL
,	NULL
we	NULL
have	NULL
used	NULL
a	NULL
powerful	NULL
PTPase	NULL
inhibitor	NULL
,	NULL
vanadate	NULL
peroxide	NULL
(	NULL
pervanadate	NULL
)	NULL
,	NULL
to	NULL
alter	NULL
the	NULL
equilibrium	NULL
between	NULL
phosphorylation	NULL
and	NULL
dephosphorylation	NULL
reactions	NULL
.	NULL

Mixing	NULL
orthovanadate	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
forms	NULL
vanadyl	NULL
hydroperoxide	NULL
(	NULL
V*+*OOH	NULL
)	NULL
also	NULL
termed	NULL
vanadate	NULL
peroxide	NULL
or	NULL
pervanadate	NULL
[	NULL
26	NULL
]	NULL
.	NULL

This	NULL
compound	NULL
has	NULL
been	NULL
proven	NULL
to	NULL
be	NULL
a	NULL
powerful	NULL
activator	NULL
of	NULL
platelets	NULL
[	NULL
27	NULL
]	NULL
and	NULL
myeloid	NULL
cells	NULL
[	NULL
28,29	NULL
]	NULL
and	NULL
to	NULL
be	NULL
an	NULL
insulinomimetic	NULL
agent	NULL
[	NULL
30	NULL
]	NULL
.	NULL

Its	NULL
effects	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
an	NULL
important	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
with	NULL
activation	NULL
of	NULL
the	NULL
insulin-receptor	NULL
tyrosine	NULL
kinase	NULL
[	NULL
31,32	NULL
]	NULL
.	NULL

We	NULL
show	NULL
that	NULL
inhibition	NULL
of	NULL
PTPases	NULL
by	NULL
pervanadate	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
human	NULL
leukaemic	NULL
line	NULL
Jurkat	NULL
results	NULL
in	NULL
generation	NULL
of	NULL
early	NULL
[	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
Ick	NULL
and	NULL
fyn	NULL
activation	NULL
,	NULL
Ca*®*	NULL
fluxes	NULL
,	NULL
c-fos	NULL
induction	NULL
,	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
Abbreviations	NULL
used	NULL
:	NULL
PTK	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
;	NULL
PTPase	NULL
,	NULL
protein	NULL
tyrosine	NULL
phosphatase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
mAb	NULL
,	NULL
monocional	NULL
antibody	NULL
;	NULL
TeR-CD3	NULL
,	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
complex	NULL
;	NULL
pNPP	NULL
,	NULL
p-nitrophenyl	NULL
phosphate	NULL
;	NULL
PLCy1	NULL
,	NULL
phospholipase	NULL
Cy1	NULL
;	NULL
IP3	NULL
,	NULL
inositol	NULL
trisphosphate	NULL
;	NULL
PMSF	NULL
,	NULL
phenylimethanesulphonyl	NULL
fluoride	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
;	NULL
Facs	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C.	NULL
*	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

164	NULL
V.	NULL
Imbert	NULL
and	NULL
others	NULL
«	NULL
B	NULL
)	NULL
activation	NULL
]	NULL
as	NULL
well	NULL
as	NULL
late	NULL
[	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
production	NULL
,	NULL
IL-2	NULL
receptor	NULL
«	NULL
-chain	NULL
and	NULL
CD69	NULL
expression	NULL
}	NULL
events	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
,	NULL
although	NULL
PTPases	NULL
are	NULL
necessary	NULL
to	NULL
deliver	NULL
a	NULL
positive	NULL
signal	NULL
for	NULL
some	NULL
PTK	NULL
activity	NULL
[	NULL
33-35	NULL
]	NULL
,	NULL
they	NULL
also	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Antibodies	NULL
and	NULL
chemicals	NULL
Anti-CD3	NULL
and	NULL
anti-CD25	NULL
mAbs	NULL
were	NULL
purchased	NULL
from	NULL
Immunotech	NULL
(	NULL
Marseille	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Anti-CD69	NULL
mAb	NULL
was	NULL
from	NULL
Beckton	NULL
Dickinson	NULL
(	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Reagents	NULL
for	NULL
IL-2	NULL
e.l.is.a	NULL
.	NULL

were	NULL
given	NULL
by	NULL
Dr.	NULL
Bernard	NULL
Ferrua	NULL
(	NULL
INSERM	NULL
U343	NULL
)	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
1l3-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
Ca*	NULL
ionophore	NULL
(	NULL
A23187	NULL
)	NULL
,	NULL
phenylmethanesulphonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
orthovanadate	NULL
,	NULL
H,0	NULL
,	NULL
,	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
ovalbumin	NULL
,	NULL
BSA	NULL
,	NULL
Nonidet	NULL
P40	NULL
,	NULL
catalase	NULL
,	NULL
luciferin	NULL
and	NULL
Indo-1-AM	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
MO	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Enolase	NULL
was	NULL
from	NULL
Boehringer	NULL
(	NULL
Meylan	NULL
,	NULL
France	NULL
)	NULL
.	NULL

All	NULL
reagents	NULL
for	NULL
Northern-blot	NULL
analysis	NULL
were	NULL
from	NULL
Appligene	NULL
(	NULL
Pleasanyon	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

The	NULL
c-fos	NULL
plasmid	NULL
for	NULL
transient	NULL
transfection	NULL
experiments	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Jun	NULL
Tsuji	NULL
(	NULL
Nagoya	NULL
University	NULL
,	NULL
Nagoya	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

Antiserum	NULL
against	NULL
Ick	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Dr.	NULL
Siegmund	NULL
Fischer	NULL
(	NULL
INSERM	NULL
U332	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Anti-phosphotyrosine	NULL
mAb	NULL
4G10	NULL
,	NULL
fyn	NULL
antiserum	NULL
and	NULL
PLCyl	NULL
antiserum	NULL
were	NULL
from	NULL
UBI	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Cell	NULL
culture	NULL
Cells	NULL
of	NULL
the	NULL
human	NULL
leukaemic	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
50	NULL
units/ml	NULL
penicillin	NULL
,	NULL
50	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
pyruvate	NULL
and	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Gibco	NULL
,	NULL
Cergy	NULL
Pontoise	NULL
,	NULL
France	NULL
)	NULL
CD4S-negative	NULL
variants	NULL
of	NULL
Jurkat	NULL
obtained	NULL
by	NULL
Facs	NULL
(	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
)	NULL
sorting	NULL
have	NULL
been	NULL
described	NULL
elsewhere	NULL
[	NULL
22	NULL
]	NULL
.	NULL

Preparation	NULL
of	NULL
vanadate	NULL
and	NULL
pervanadate	NULL
solutions	NULL
The	NULL
vanadate	NULL
solution	NULL
was	NULL
prepared	NULL
in	NULL
incubation	NULL
buffer	NULL
(	NULL
30	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
4	NULL
mM	NULL
KCl	NULL
,	NULL
0.8	NULL
mM	NULL
MgSO	NULL
,	NULL
,	NULL
1.8	NULL
mM	NULL
CaCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
glucose	NULL
)	NULL
.	NULL

Pervanadate	NULL
was	NULL
obtained	NULL
by	NULL
mixing	NULL
vanadate	NULL
with	NULL
1	NULL
mM	NULL
H,0	NULL
,	NULL
,	NULL
for	NULL
15	NULL
min	NULL
at	NULL
22	NULL
°C	NULL
.	NULL

This	NULL
was	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
catalase	NULL
(	NULL
200	NULL
ug/ml	NULL
)	NULL
to	NULL
remove	NULL
residual	NULL
H	NULL
,	NULL
O	NULL
,	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
pervanadate	NULL
generated	NULL
is	NULL
denoted	NULL
by	NULL
the	NULL
vanadate	NULL
concentration	NULL
added	NULL
to	NULL
the	NULL
mixture	NULL
[	NULL
31	NULL
]	NULL
.	NULL

A	NULL
mixture	NULL
containing	NULL
only	NULL
catalase	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
of	NULL
pervanadate	NULL
effects	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
immunoblotting	NULL
Jurkat	NULL
cells	NULL
(	NULL
2x	NULL
10°	NULL
per	NULL
condition	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
with	NULL
various	NULL
effectors	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Reactions	NULL
were	NULL
stopped	NULL
by	NULL
cell	NULL
solubilization	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
20	NULL
mM	NULL
EDTA	NULL
,	NULL
100	NULL
4M	NULL
NaF	NULL
,	NULL
10	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P40	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
10000	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
and	NULL
supernatants	NULL
adjusted	NULL
with	NULL
concentrated	NULL
SDS	NULL
sample	NULL
buffer	NULL
.	NULL

For	NULL
immunoprecipitation	NULL
,	NULL
lysates	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
rabbit	NULL
antiserum	NULL
against	NULL
PLCy1	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
Protein	NULL
A-Sepharose	NULL
beads	NULL
were	NULL
then	NULL
added	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
precipitates	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
lysis	NULL
buffer	NULL
.	NULL

Proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS/PAGE	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
,	NULL
U.S.A.	NULL
)	NULL
in	NULL
a	NULL
solution	NULL
of	NULL
Tris	NULL
(	NULL
20	NULL
mM	NULL
)	NULL
,	NULL
glycine	NULL
(	NULL
150	NULL
mM	NULL
)	NULL
and	NULL
methanol	NULL
(	NULL
20	NULL
%	NULL
)	NULL
at	NULL
55	NULL
V	NULL
for	NULL
5	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
saturated	NULL
with	NULL
blocking	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
%	NULL
BSA	NULL
,	NULL
1	NULL
%	NULL
ovalbumin	NULL
,	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
0.02	NULL
%	NULL
NaN	NULL
,	NULL
)	NULL
for	NULL
18	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
then	NULL
probed	NULL
with	NULL
a	NULL
mouse	NULL
anti-phosphotyrosine	NULL
mAb	NULL
(	NULL
4G	NULL
10	NULL
)	NULL
at	NULL
1	NULL
ug/ml	NULL
in	NULL
blocking	NULL
buffer	NULL
,	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
filters	NULL
were	NULL
washed	NULL
in	NULL
TNA	NULL
(	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
0.02	NULL
%	NULL
NaN	NULL
,	NULL
)	NULL
and	NULL
TNAT	NULL
(	NULL
TNA	NULL
+0.05	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
.	NULL

Bound	NULL
antibodies	NULL
were	NULL
revealed	NULL
after	NULL
incubation	NULL
with	NULL
alkaline	NULL
phosphatase-conjugated	NULL
anti-mouse	NULL
antibodies	NULL
(	NULL
1	NULL
:	NULL
5000	NULL
dilution	NULL
in	NULL
blocking	NULL
buffer	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
followed	NULL
by	NULL
a	NULL
colorimetric	NULL
reaction	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
PLCy1	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
immunoreactive	NULL
proteins	NULL
were	NULL
detected	NULL
by	NULL
using	NULL
'**I-Protein	NULL
A	NULL
and	NULL
the	NULL
membrane	NULL
was	NULL
autoradiographed	NULL
(	NULL
3M	NULL
Trimax	NULL
films	NULL
)	NULL
.	NULL

Kinase	NULL
assay	NULL
After	NULL
cell	NULL
stimulation	NULL
and	NULL
lysis	NULL
as	NULL
described	NULL
above	NULL
(	NULL
10	NULL
``	NULL
cells/	NULL
condition	NULL
)	NULL
,	NULL
Ick	NULL
and	NULL
fyn	NULL
were	NULL
precipitated	NULL
with	NULL
specific	NULL
antibodies	NULL
(	NULL
1:100	NULL
)	NULL
.	NULL

Immune	NULL
complexes	NULL
were	NULL
collected	NULL
using	NULL
Protein	NULL
A-Sepharose	NULL
.	NULL

After	NULL
three	NULL
washes	NULL
with	NULL
lysis	NULL
buffer	NULL
and	NULL
one	NULL
with	NULL
kinase	NULL
buffer	NULL
(	NULL
30	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
6.8	NULL
,	NULL
5	NULL
mM	NULL
MnCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
MgC1	NULL
,	NULL
)	NULL
,	NULL
kinase	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
adding	NULL
2	NULL
xCi	NULL
of	NULL
[	NULL
y-*°P	NULL
]	NULL
JATP	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
acid-treated	NULL
enolase	NULL
,	NULL
for	NULL
10	NULL
min	NULL
at	NULL
25	NULL
°C	NULL
.	NULL

Samples	NULL
were	NULL
subjected	NULL
to	NULL
SDS/PAGE	NULL
(	NULL
10	NULL
%	NULL
gels	NULL
)	NULL
,	NULL
and	NULL
phosphoproteins	NULL
were	NULL
analysed	NULL
by	NULL
autoradiography	NULL
.	NULL

Kinase	NULL
activity	NULL
was	NULL
quantified	NULL
by	NULL
Cerenkov	NULL
counting	NULL
of	NULL
enolase	NULL
bands	NULL
.	NULL

Phosphatase	NULL
assay	NULL
Membrane	NULL
and	NULL
cytosolic	NULL
fractions	NULL
were	NULL
prepared	NULL
from	NULL
stimulated	NULL
cells	NULL
.	NULL

CD45	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
Jurkat	NULL
lysates	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
mAb	NULL
.	NULL

PTPase	NULL
activity	NULL
was	NULL
assayed	NULL
against	NULL
the	NULL
phosphotyrosine	NULL
analogue	NULL
p-nitrophenyl	NULL
phosphate	NULL
(	NULL
pNPP	NULL
,	NULL
10	NULL
mM	NULL
)	NULL
at	NULL
37	NULL
°C	NULL
by	NULL
following	NULL
the	NULL
release	NULL
of	NULL
p-nitrophenol	NULL
at	NULL
410	NULL
nm	NULL
.	NULL

Measurement	NULL
of	NULL
Ca*+*	NULL
fluxes	NULL
Cells	NULL
at	NULL
10'/ml	NULL
were	NULL
loaded	NULL
with	NULL
3	NULL
4M	NULL
Indo-1	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

They	NULL
were	NULL
then	NULL
washed	NULL
once	NULL
,	NULL
resuspended	NULL
in	NULL
fresh	NULL
medium	NULL
at	NULL
10°	NULL
cells/ml	NULL
and	NULL
stored	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
dark	NULL
until	NULL
tested	NULL
.	NULL

The	NULL
analysis	NULL
was	NULL
done	NULL
on	NULL
an	NULL
ATC	NULL
3000	NULL
cell	NULL
sorter	NULL
(	NULL
Odam	NULL
Brucker	NULL
,	NULL
Wissembourg	NULL
,	NULL
France	NULL
)	NULL
.	NULL

The	NULL
fluorescence	NULL
intensity	NULL
ratio	NULL
405	NULL
nm	NULL
(	NULL
Ca**-Indo-1	NULL
complex	NULL
)	NULL
/495	NULL
nm	NULL
(	NULL
free	NULL
Indo-1	NULL
)	NULL
allows	NULL
the	NULL
evaluation	NULL
of	NULL
the	NULL
changes	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
concentration	NULL
.	NULL

Northern-blot	NULL
analysis	NULL
Total	NULL
RNA	NULL
was	NULL
prepared	NULL
by	NULL
acid	NULL
guanidium	NULL
thiocyanate/	NULL
phenol/chloroform	NULL
extraction	NULL
[	NULL
36	NULL
]	NULL
.	NULL

Portions	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
under	NULL
denaturating	NULL
conditions	NULL
and	NULL
transferred	NULL
to	NULL
Hybond	NULL
N+	NULL
nylon	NULL
membrane	NULL
.	NULL

The	NULL
different	NULL
probes	NULL
were	NULL
labelled	NULL
by	NULL
random	NULL
priming	NULL
.	NULL

Hybridization	NULL
was	NULL
performed	NULL
overnight	NULL
at	NULL
65°C	NULL
and	NULL
the	NULL
filters	NULL
were	NULL
washed	NULL
at	NULL
65	NULL
°C	NULL
by	NULL
the	NULL
procedure	NULL
of	NULL
Church	NULL
and	NULL
Gilbert	NULL
[	NULL
37	NULL
]	NULL
.	NULL

Transient	NULL
transfection	NULL
experiments	NULL
Cells	NULL
were	NULL
washed	NULL
in	NULL
RPMI	NULL
1640	NULL
,	NULL
and	NULL
then	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
(	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
137	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
KCI	NULL
,	NULL
0.6	NULL
mM	NULL
Regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
by	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
165	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
,7H,0	NULL
,	NULL
0.7	NULL
mM	NULL
MgC1	NULL
,	NULL
,	NULL
0.7	NULL
mM	NULL
CaC1	NULL
,	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
a	NULL
plasmid	NULL
carrying	NULL
the	NULL
c-fos	NULL
gene	NULL
promoter	NULL
linked	NULL
to	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
DEAE-dextran	NULL
(	NULL
500	NULL
pg/ml	NULL
!	NULL
)	NULL

and	NULL
heparin	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
After	NULL
30	NULL
min	NULL
of	NULL
incubation	NULL
,	NULL
they	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
4M	NULL
chloroquin	NULL
for	NULL
3-4	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
maintained	NULL
for	NULL
24	NULL
h	NULL
in	NULL
RPMI	NULL
1640	NULL
plus	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
stimulation	NULL
by	NULL
various	NULL
effectors	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
solubilized	NULL
in	NULL
luciferase	NULL
assay	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
5	NULL
mM	NULL
ATP	NULL
,	NULL
15	NULL
mM	NULL
MgSO	NULL
,	NULL
)	NULL
.	NULL

Cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
repeated	NULL
freezing	NULL
and	NULL
thawing	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
on	NULL
10	NULL
ug	NULL
of	NULL
cell	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
mM	NULL
luciferin	NULL
on	NULL
a	NULL
photon-counting	NULL
luminometer	NULL
(	NULL
Biolumat	NULL
;	NULL
Berthold	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility-shift	NULL
assay	NULL
Preparations	NULL
of	NULL
cellular	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
fractions	NULL
were	NULL
made	NULL
by	NULL
the	NULL
procedure	NULL
of	NULL
Osborn	NULL
et	NULL
al	NULL
.	NULL

[	NULL
38	NULL
]	NULL
,	NULL
modified	NULL
by	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

[	NULL
39	NULL
]	NULL
.	NULL

Briefly	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
in	NULL
cold	NULL
PBS	NULL
.	NULL

The	NULL
cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
30	NULL
ul	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P40	NULL
)	NULL
per	NULL
10°	NULL
cells	NULL
and	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Nuclei	NULL
were	NULL
collected	NULL
by	NULL
a	NULL
brief	NULL
centrifugation	NULL
in	NULL
a	NULL
Microfuge	NULL
,	NULL
and	NULL
supernatants	NULL
(	NULL
cytosolic	NULL
fractions	NULL
)	NULL
were	NULL
removed	NULL
and	NULL
stored	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

Nuclear	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
45	NULL
l	NULL
of	NULL
buffer	NULL
B	NULL
(	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
per	NULL
10°	NULL
nuclei	NULL
and	NULL
centrifuged	NULL
at	NULL
10000	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatants	NULL
(	NULL
nuclear	NULL
fractions	NULL
)	NULL
were	NULL
transferred	NULL
to	NULL
new	NULL
tubes	NULL
and	NULL
diluted	NULL
in	NULL
67	NULL
wl	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
per	NULL
10°	NULL
nuclei	NULL
and	NULL
stored	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

Mobility-shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
probe	NULL
was	NULL
a	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-	NULL
«	NULL
B-binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
(	NULL
5'-GATCCAAGGGACTTTCCATG-3	NULL
'	NULL
)	NULL
[	NULL
40	NULL
]	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
probe	NULL
was	NULL
end-labelled	NULL
with	NULL
[	NULL
y-**P	NULL
]	NULL
JATP	NULL
using	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
samples	NULL
for	NULL
20	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
separated	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
6	NULL
%	NULL
non-denaturating	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
x	NULL
TBE	NULL
(	NULL
Tris/borate	NULL
45	NULL
mM	NULL
,	NULL
EDTA	NULL
1mM	NULL
)	NULL
.	NULL

The	NULL
dried	NULL
gels	NULL
were	NULL
subjected	NULL
to	NULL
autoradiography	NULL
(	NULL
Kodak	NULL
X-OMAT	NULL
films	NULL
)	NULL
.	NULL

Surface	NULL
staining	NULL
Cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
BSA	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
with	NULL
saturating	NULL
concentrations	NULL
of	NULL
antibodies	NULL
,	NULL
and	NULL
then	NULL
washed	NULL
with	NULL
the	NULL
same	NULL
buffer	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
for	NULL
another	NULL
30	NULL
min	NULL
period	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
antibodies	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
resuspended	NULL
at	NULL
10°	NULL
cells/ml	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
on	NULL
an	NULL
ATC	NULL
3000	NULL
cell	NULL
sorter	NULL
.	NULL

Measurement	NULL
of	NULL
IL-2	NULL
secretion	NULL
Jurkat	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
at	NULL
10°	NULL
cells/ml	NULL
.	NULL

Various	NULL
effectors	NULL
were	NULL
added	NULL
and	NULL
cells	NULL
incubated	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
humidified	NULL
atmosphere	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
centrifuged	NULL
at	NULL
800	NULL
g	NULL
for	NULL
10	NULL
min	NULL
.	NULL

IL-2	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
sequential	NULL
sandwich	NULL
e.l.i.s.a	NULL
.	NULL

as	NULL
previously	NULL
described	NULL
[	NULL
41	NULL
]	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
lymphokine	NULL
was	NULL
first	NULL
extracted	NULL
from	NULL
supernatants	NULL
with	NULL
a	NULL
rabbit	NULL
anti-	NULL
(	NULL
recombinant	NULL
IL-	NULL
2	NULL
)	NULL
IgG	NULL
immobilized	NULL
on	NULL
to	NULL
polystyrene	NULL
microtitre	NULL
plates	NULL
and	NULL
revealed	NULL
by	NULL
an	NULL
anti-IL-2	NULL
Fab	NULL
'	NULL
fragment	NULL
conjugated	NULL
to	NULL
peroxidase	NULL
.	NULL

RESULTS	NULL
Pervanadate	NULL
inhibits	NULL
cellular	NULL
PTPase	NULL
activity	NULL
We	NULL
have	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
pervanadate	NULL
on	NULL
Jurkat	NULL
PTPase	NULL
activities	NULL
towards	NULL
a	NULL
phosphotyrosine	NULL
analogue	NULL
,	NULL
pNPP	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Pervanadate	NULL
abolished	NULL
total	NULL
as	NULL
well	NULL
as	NULL
cytosolic	NULL
and	NULL
membrane	NULL
PTPase	NULL
activities	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

Its	NULL
effect	NULL
was	NULL
maximal	NULL
at	NULL
100	NULL
4M	NULL
.	NULL

Because	NULL
CD45	NULL
is	NULL
the	NULL
most	NULL
abundant	NULL
PTPase	NULL
on	NULL
the	NULL
T-cell	NULL
surface	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effects	NULL
of	NULL
pervanadate	NULL
on	NULL
CD45	NULL
activity	NULL
.	NULL

Similarly	NULL
to	NULL
its	NULL
effect	NULL
on	NULL
total	NULL
PTPase	NULL
activities	NULL
,	NULL
pervanadate	NULL
inhibited	NULL
the	NULL
activity	NULL
of	NULL
immunoprecipitated	NULL
CD45	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

Intact	NULL
Jurkat	NULL
cells	NULL
had	NULL
a	NULL
low	NULL
ecto-pNPP	NULL
hydrolysis	NULL
activity	NULL
which	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
pervanadate	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
activity	NULL
may	NULL
correspond	NULL
to	NULL
alkaline	NULL
phosphatase	NULL
and	NULL
represented	NULL
less	NULL
than	NULL
20	NULL
%	NULL
of	NULL
membrane	NULL
activity	NULL
as	NULL
calculated	NULL
in	NULL
CD4S5-deficient	NULL
cells	NULL
[	NULL
22	NULL
]	NULL
.	NULL

It	NULL
is	NULL
unlikely	NULL
that	NULL
alkaline	NULL
phosphatase	NULL
is	NULL
involved	NULL
in	NULL
pervanadate	NULL
action	NULL
,	NULL
as	NULL
its	NULL
activity	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
inhibitor	NULL
.	NULL

Pervanadate	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jurkat	NULL
cellular	NULL
proteins	NULL
After	NULL
activation	NULL
,	NULL
for	NULL
10	NULL
min	NULL
,	NULL
of	NULL
intact	NULL
Jurkat	NULL
cells	NULL
with	NULL
various	NULL
effectors	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
total	NULL
cell	NULL
lysates	NULL
was	NULL
analysed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

Figure	NULL
1	NULL
(	NULL
a	NULL
)	NULL
shows	NULL
that	NULL
cell	NULL
stimulation	NULL
with	NULL
pervanadate	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
dramatically	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
proteins	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

At	NULL
the	NULL
same	NULL
concentration	NULL
,	NULL
vanadate	NULL
alone	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
most	NULL
prominent	NULL
substrates	NULL
induced	NULL
by	NULL
pervanadate	NULL
display	NULL
molecular	NULL
masses	NULL
of	NULL
230	NULL
,	NULL
210	NULL
,	NULL
175	NULL
,	NULL
150	NULL
,	NULL
145	NULL
,	NULL
120	NULL
,	NULL
115	NULL
,	NULL
105	NULL
,	NULL
89	NULL
,	NULL
72	NULL
,	NULL
70	NULL
,	NULL
59	NULL
,	NULL
50	NULL
,	NULL
42	NULL
,	NULL
38	NULL
,	NULL
36	NULL
,	NULL
35	NULL
,	NULL
30	NULL
and	NULL
22	NULL
kDa	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
pervanadate	NULL
was	NULL
dose-dependent	NULL
:	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
detectable	NULL
at	NULL
concentrations	NULL
as	NULL
low	NULL
as	NULL
25	NULL
aM	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
increased	NULL
steeply	NULL
up	NULL
to	NULL
1	NULL
mM	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
control	NULL
conditions	NULL
containing	NULL
only	NULL
catalase	NULL
and	NULL
H,0	NULL
,	NULL
,	NULL
without	NULL
vanadate	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
tyrosine	NULL
phosphorylation	NULL
levels	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
unstimulated	NULL
cells	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
requires	NULL
generation	NULL
of	NULL
pervanadate	NULL
.	NULL

A	NULL
time-course	NULL
experiment	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
showed	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
noticeable	NULL
1	NULL
min	NULL
after	NULL
addition	NULL
of	NULL
pervanadate	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
and	NULL
peaked	NULL
around	NULL
15	NULL
min	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

No	NULL
Table	NULL
1	NULL
Intact	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
pervanadate	NULL
,	NULL
and	NULL
PTPase	NULL
activity	NULL
was	NULL
measured	NULL
on	NULL
total	NULL
lysate	NULL
or	NULL
membrane	NULL
or	NULL
cytosolic	NULL
fractions	NULL
.	NULL

For	NULL
CD45	NULL
PTPase	NULL
activity	NULL
,	NULL
CD45	NULL
molecules	NULL
were	NULL
isolated	NULL
by	NULL
immunoprecipitation	NULL
with	NULL
mAbs	NULL
.	NULL

The	NULL
PTPase	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
phosphotyrosine	NULL
analogue	NULL
,	NULL
pNPP	NULL
,	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

The	NULL
release	NULL
of	NULL
p-nitrophenol	NULL
was	NULL
followed	NULL
at	NULL
410	NULL
nm	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Inhibition	NULL
of	NULL
cellular	NULL
PTPase	NULL
activity	NULL
by	NULL
pervanadate	NULL
Total	NULL
Cytosolic	NULL
Membrane	NULL
CO45	NULL
PTPase	NULL
PTPase	NULL
PTPase	NULL
PTPase	NULL
Conditions	NULL
activity	NULL
activity	NULL
activity	NULL
activity	NULL
Basal	NULL
1.294	NULL
0.520	NULL
0.349	NULL
1.053	NULL
Pervanadate	NULL
100	NULL
M	NULL
0.182	NULL
0.175	NULL
0.093	NULL
0.053	NULL
10	NULL
4M	NULL
0.400	NULL
0.265	NULL
0.175	NULL
0.269	NULL
1	NULL
aM	NULL
1.263	NULL
0.621	NULL
0.184	NULL
0.601	NULL
166	NULL
V.	NULL
Imbert	NULL
and	NULL
others	NULL
(	NULL
b	NULL
)	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
(	NULL
kDa	NULL
)	NULL
(	NULL
kDa	NULL
)	NULL
-	NULL
200	NULL
-	NULL
200	NULL
-	NULL
97	NULL
-	NULL
-	NULL
97	NULL
-486	NULL
-	NULL
69	NULL
-	NULL
46	NULL
-	NULL
30	NULL
-21	NULL
-	NULL
30	NULL
-	NULL
21	NULL
$	NULL
,	NULL
B	NULL
,	NULL
B	NULL
,	NULL
N	NULL
0	NULL
1	NULL
5	NULL
10	NULL
15	NULL
30	NULL
60	NULL
LE	NULL
.Eol.olo	NULL
!	NULL

£	NULL
Q7\\\\\\	NULL
NQQ	NULL
(	NULL
OQQ/	NULL
co	NULL
pV	NULL
(	NULL
500	NULL
M	NULL
)	NULL
(	NULL
L	NULL
\\\	NULL
``	NULL
Qq	NULL
q	NULL
8	NULL
Figure	NULL
1	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
proteins	NULL
by	NULL
pervanadate	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
a	NULL
)	NULL
Dose-response	NULL
effect	NULL
of	NULL
pervanadate	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
orthovanadate	NULL
(	NULL
VO	NULL
,	NULL
)	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
,	NULL
pervanadate	NULL
(	NULL
pV	NULL
)	NULL
at	NULL
different	NULL
concentrations	NULL
or	NULL
control	NULL
(	NULL
H,0	NULL
,	NULL
+	NULL
catalase	NULL
)	NULL
.	NULL

(	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
pervanadate	NULL
effect	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
(	NULL
min	NULL
)	NULL
with	NULL
pervanadate	NULL
(	NULL
500	NULL
M	NULL
)	NULL
.	NULL

Proteins	NULL
from	NULL
cell	NULL
lysates	NULL
were	NULL
separated	NULL
by	NULL
SDS/PAGE	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon	NULL
membranes	NULL
for	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
antibody	NULL
was	NULL
revealed	NULL
by	NULL
an	NULL
alkaline	NULL
phosphatase-conjugated	NULL
anti-mouse	NULL
antibody	NULL
.	NULL

decrease	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
observed	NULL
up	NULL
to	NULL
1	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
the	NULL
effect	NULL
of	NULL
three	NULL
different	NULL
PTK	NULL
inhibitors	NULL
,	NULL
namely	NULL
genistein	NULL
(	NULL
100	NULL
M	NULL
)	NULL
,	NULL
staurosporine	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
and	NULL
herbimycin	NULL
A	NULL
(	NULL
10	NULL
M	NULL
)	NULL
,	NULL
on	NULL
the	NULL
<	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
pervanadate	NULL
.	NULL

Genistein	NULL
and	NULL
staurosporine	NULL
were	NULL
preincubated	NULL
for	NULL
10	NULL
min	NULL
while	NULL
herbimycin	NULL
A	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
18	NULL
h	NULL
before	NULL
stimulation	NULL
.	NULL

The	NULL
inhibitors	NULL
,	NULL
especially	NULL
herbimycin	NULL
A	NULL
,	NULL
dramatically	NULL
counteracted	NULL
the	NULL
effect	NULL
of	NULL
pervanadate	NULL
.	NULL

However	NULL
,	NULL
complete	NULL
inhibition	NULL
was	NULL
not	NULL
observed	NULL
probably	NULL
because	NULL
of	NULL
the	NULL
large	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

In	NULL
a	NULL
control	NULL
experiment	NULL
,	NULL
we	NULL
verified	NULL
that	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
inhibitor	NULL
,	NULL
H7	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
pervanadate	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
pervanadate	NULL
requires	NULL
active	NULL
PTK	NULL
.	NULL

Pervanadate	NULL
activates	NULL
Ick	NULL
and	NULL
fyn	NULL
tyrosine	NULL
kinases	NULL
Analysis	NULL
of	NULL
Ick	NULL
and	NULL
fyn	NULL
activity	NULL
was	NULL
performed	NULL
on	NULL
immunoprecipitates	NULL
from	NULL
pervanadate-treated	NULL
intact	NULL
Jurkat	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
3	NULL
,	NULL
a	NULL
10	NULL
min	NULL
stimulation	NULL
with	NULL
pervanadate	NULL
induced	NULL
a	NULL
4.3-	NULL
and	NULL
a	NULL
2.6-fold	NULL
increase	NULL
in	NULL
kinase	NULL
activity	NULL
of	NULL
Ick	NULL
and	NULL
fyn	NULL
respectively	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
autophosphorylation	NULL
level	NULL
of	NULL
the	NULL
kinases	NULL
was	NULL
also	NULL
observed	NULL
,	NULL
as	NULL
well	NULL
as	NULL
several	NULL
retarded	NULL
bands	NULL
corresponding	NULL
to	NULL
different	NULL
phosphorylated	NULL
forms	NULL
of	NULL
the	NULL
kinases	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
after	NULL
treatment	NULL
of	NULL
the	NULL
gels	NULL
with	NULL
KOH	NULL
to	NULL
hydrolyse	NULL
phosphoserine	NULL
and	NULL
phosphothreonine	NULL
residues	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
mostly	NULL
occurred	NULL
on	NULL
(	NULL
kDa	NULL
)	NULL
-	NULL
200	NULL
-	NULL
97	NULL
-	NULL
69	NULL
||	NULL
-	NULL
46	NULL
{	NULL
|	NULL
-30	NULL
-	NULL
21	NULL
Figure	NULL
2	NULL
-	NULL
Effects	NULL
of	NULL
PTK	NULL
inhibitors	NULL
on	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
pervanadate	NULL
Jurkat	NULL
cells	NULL
were	NULL
preincubated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
genistein	NULL
(	NULL
100	NULL
«	NULL
M	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
staurosporine	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
,	NULL
for	NULL
18	NULL
h	NULL
,	NULL
with	NULL
herbimycin	NULL
A	NULL
(	NULL
10	NULL
M	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
pervanadate	NULL
(	NULL
200	NULL
M	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
was	NULL
revealed	NULL
by	NULL
a	NULL
Western-blotting	NULL
technique	NULL
using	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
control	NULL
,	NULL
no	NULL
stimulation	NULL
or	NULL
preincubation	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
stimulation	NULL
with	NULL
pervanadate	NULL
with	NULL
no	NULL
preincubation	NULL
.	NULL

p561ck	NULL
p59fyn	NULL
0	NULL
pV	NULL
0	NULL
pV	NULL
-	NULL
pﬁolck	NULL
__	NULL
p59fV	NULL
”	NULL
I	NULL
-	NULL
p56	NULL
!	NULL

-	NULL
Enolase	NULL
W	NULL
-Enolase	NULL
IgG	NULL
[	NULL
OTC	NULL
0	NULL
I	NULL
0	NULL
pV	NULL
-	NULL
Enolase	NULL
Figure	NULL
3	NULL
-	NULL
Pervanadate	NULL
induction	NULL
of	NULL
activation	NULL
of	NULL
Ick	NULL
and	NULL
fyn	NULL
PTKs	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
or	NULL
not	NULL
with	NULL
pervanadate	NULL
(	NULL
pV	NULL
;	NULL
200	NULL
M	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

fyn	NULL
and	NULL
Ick	NULL
were	NULL
precipitated	NULL
using	NULL
specific	NULL
antisera	NULL
.	NULL

Non-immune	NULL
rabbit	NULL
serum	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Kinase	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-3ZP1ATP	NULL
and	NULL
enolase	NULL
as	NULL
exogenous	NULL
substrate	NULL
.	NULL

Samples	NULL
were	NULL
separated	NULL
by	NULL
SDS/PAGE	NULL
and	NULL
phosphoproteins	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Numbers	NULL
correspond	NULL
to	NULL
increase	NULL
in	NULL
kinase	NULL
activity	NULL
as	NULL
quantified	NULL
by	NULL
Gerenkov	NULL
counting	NULL
of	NULL
enolase	NULL
bands	NULL
.	NULL

tyrosine	NULL
residues	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
judged	NULL
by	NULL
Western	NULL
blotting	NULL
or	NULL
Facs	NULL
analysis	NULL
with	NULL
kinase-specific	NULL
antibodies	NULL
,	NULL
pervanadate	NULL
did	NULL
not	NULL
modify	NULL
Ick	NULL
and	NULL
fyn	NULL
levels	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
Regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
by	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
167	NULL
Fluorescence	NULL
ratio	NULL
(	NULL
arbitrary	NULL
units	NULL
)	NULL
60	NULL
~	NULL
50	NULL
7	NULL
40	NULL
30	NULL
20	NULL
(	NULL
a	NULL
)	NULL
(	NULL
b	NULL
)	NULL
2°	NULL
3	NULL
L	NULL
4	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
Figure	NULL
4	NULL
-	NULL
Pervanadate	NULL
induction	NULL
of	NULL
Ca**	NULL
mobilization	NULL
(	NULL
a	NULL
)	NULL
Jurkat	NULL
celts	NULL
were	NULL
labelled	NULL
with	NULL
-the	NULL
fluorescent	NULL
Ca	NULL
``	NULL
+*	NULL
indicator	NULL
Indo-1	NULL
(	NULL
3	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
0.5	NULL
g/m	NULL
!	NULL
)	NULL

(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
200	NULL
wM	NULL
pervanadate	NULL
(	NULL
@	NULL
R	NULL
)	NULL
or	NULL
a	NULL
control	NULL
solution	NULL
containing	NULL
only	NULL
catalase	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
(	NULL
(	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Effect	NULL
of	NULL
different	NULL
concentrations	NULL
of	NULL
pervanadate	NULL
.	NULL

Indo-1-loaded	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
0.5	NULL
g/m	NULL
!	NULL
)	NULL

(	NULL
0	NULL
)	NULL
.	NULL

different	NULL
concentrations	NULL
of	NULL
pervanadate	NULL
[	NULL
10	NULL
«	NULL
M	NULL
(	NULL
a	NULL
)	NULL
,	NULL
100	NULL
M	NULL
(	NULL
@	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
(	NULL
RR	NULL
)	NULL
]	NULL
or	NULL
a	NULL
control	NULL
solution	NULL
containing	NULL
only	NULL
catalase	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
(	NULL
A	NULL
)	NULL
.	NULL

The	NULL
fluorescence	NULL
intensities	NULL
at	NULL
405	NULL
nm	NULL
and	NULL
495	NULL
nm	NULL
were	NULL
analysed	NULL
on	NULL
a	NULL
cell	NULL
sorter	NULL
.	NULL

The	NULL
ratio	NULL
405/495	NULL
is	NULL
displayed	NULL
which	NULL
corresponds	NULL
to	NULL
the	NULL
intracellular	NULL
free	NULL
concentration	NULL
.	NULL

the	NULL
effect	NULL
we	NULL
observed	NULL
was	NULL
due	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
their	NULL
specific	NULL
activity	NULL
.	NULL

Pervanadate	NULL
induces	NULL
Ca**	NULL
influx	NULL
and	NULL
stimulates	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLCy1	NULL
We	NULL
then	NULL
analysed	NULL
the	NULL
induction	NULL
of	NULL
Ca**	NULL
fluxes	NULL
in	NULL
Indo-1-loaded	NULL
Jurkat	NULL
cells	NULL
.	NULL

Figure	NULL
4	NULL
(	NULL
a	NULL
)	NULL
shows	NULL
that	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca®*	NULL
concentration	NULL
(	NULL
[	NULL
Ca®	NULL
]	NULL
,	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
a	NULL
release	NULL
from	NULL
intracellular	NULL
stores	NULL
and	NULL
an	NULL
influx	NULL
of	NULL
external	NULL
Ca®*	NULL
into	NULL
the	NULL
cell	NULL
.	NULL

Pervanadate	NULL
also	NULL
caused	NULL
a	NULL
rise	NULL
in	NULL
[	NULL
Ca	NULL
``	NULL
]	NULL
)	NULL
,	NULL
,	NULL
which	NULL
was	NULL
slower	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
CD3	NULL
stimulation	NULL
,	NULL
but	NULL
reached	NULL
the	NULL
same	NULL
maximal	NULL
value	NULL
after	NULL
4-5	NULL
min	NULL
.	NULL

Control	NULL
stimulation	NULL
without	NULL
vanadate	NULL
failed	NULL
to	NULL
induce	NULL
any	NULL
inward	NULL
flux	NULL
of	NULL
Ca**	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
[	NULL
Ca®*	NULL
]	NULL
,	NULL
was	NULL
dose	NULL
C	NULL
'	NULL
C	NULL
3	NULL
2	NULL
S	NULL
#	NULL
8	NULL
&	NULL
20	NULL
7	NULL
;	NULL
T	NULL
*T	NULL
T	NULL
T	NULL
T	NULL
1	NULL
.o	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
®	NULL
§	NULL
597	NULL
(	NULL
b	NULL
)	NULL
€	NULL
$	NULL
@	NULL
®	NULL
3	NULL
£	NULL
5047	NULL
40	NULL
7	NULL
ca2+	NULL
30	NULL
A	NULL
20	NULL
F	NULL
Tt	NULL
--	NULL
t	NULL
-*	NULL
0	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
Time	NULL
(	NULL
min	NULL
}	NULL
Figure	NULL
5	NULL
Effect	NULL
of	NULL
EGTA	NULL
on	NULL
Ca	NULL
mobilization	NULL
by	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
pervanadate	NULL
Jurkat	NULL
cells	NULL
were	NULL
labelled	NULL
with	NULL
the	NULL
fluorescent	NULL
Ca**	NULL
indicator	NULL
Indo-1	NULL
(	NULL
3	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
preincubated	NULL
with	NULL
(	NULL
(	NULL
RB	NULL
)	NULL
or	NULL
without	NULL
(	NULL
)	NULL
2	NULL
mM	NULL
EGTA	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
0.5	NULL
g/m	NULL
!	NULL

of	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
a	NULL
)	NULL
or	NULL
pervanadate	NULL
(	NULL
200	NULL
M	NULL
)	NULL
(	NULL
b	NULL
)	NULL
.	NULL

The	NULL
fluorescence	NULL
intensities	NULL
at	NULL
405	NULL
nm	NULL
and	NULL
495	NULL
nm	NULL
were	NULL
analysed	NULL
on	NULL
a	NULL
cell	NULL
sorter	NULL
.	NULL

dependent	NULL
,	NULL
with	NULL
an	NULL
EC	NULL
;	NULL
,	NULL
of	NULL
approximately	NULL
50	NULL
«	NULL
M	NULL
(	NULL
Figure	NULL
4b	NULL
)	NULL
.	NULL

As	NULL
observed	NULL
for	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
pervanadate	NULL
appeared	NULL
to	NULL
be	NULL
more	NULL
efficient	NULL
than	NULL
vanadate	NULL
in	NULL
increasing	NULL
[	NULL
Ca®**	NULL
]	NULL
,	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Ca®*	NULL
chelator	NULL
EGTA	NULL
,	NULL
CD3	NULL
stimulation	NULL
resulted	NULL
in	NULL
a	NULL
transient	NULL
increase	NULL
in	NULL
[	NULL
Ca®	NULL
``	NULL
]	NULL
,	NULL
corresponding	NULL
solely	NULL
to	NULL
the	NULL
release	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
stores	NULL
,	NULL
the	NULL
Ca®*-influx	NULL
contribution	NULL
being	NULL
abrogated	NULL
(	NULL
Figure	NULL
Sa	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
EGTA	NULL
abolished	NULL
the	NULL
Ca®**	NULL
response	NULL
induced	NULL
by	NULL
pervanadate	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
this	NULL
agent	NULL
stimulated	NULL
a	NULL
Ca*®*	NULL
influx	NULL
only	NULL
.	NULL

Release	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
stores	NULL
is	NULL
mediated	NULL
by	NULL
IP	NULL
,	NULL
which	NULL
results	NULL
from	NULL
hydrolysis	NULL
of	NULL
phosphoinositol	NULL
bisphosphate	NULL
by	NULL
PLCyl	NULL
.	NULL

We	NULL
thus	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
PLCy1	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
anti-phosphotyrosine	NULL
Western	NULL
blotting	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
200	NULL
4M	NULL
pervanadate	NULL
for	NULL
2	NULL
min	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLCy1	NULL
(	NULL
Figure	NULL
6a	NULL
)	NULL
.	NULL

Under	NULL
the	NULL
same	NULL
conditions	NULL
,	NULL
pervanadate	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
amount	NULL
of	NULL
PLCyl1	NULL
as	NULL
determined	NULL
by	NULL
immunoprecipitation	NULL
from	NULL
[	NULL
**SJmethionine-labelled	NULL
cells	NULL
(	NULL
Figure	NULL
6b	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
more	NULL
slowly	NULL
migrating	NULL
168	NULL
V.	NULL
Imbert	NULL
and	NULL
others	NULL
Stimulation	NULL
:	NULL
Basal	NULL
pV	NULL
pV	NULL
(	NULL
a	NULL
)	NULL
@	NULL
»	NULL
--	NULL
PLCy1-	NULL
'	NULL
__	NULL
Ig	NULL
Figure	NULL
6	NULL
-	NULL
Pervanadate	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLCy1	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
2	NULL
min	NULL
with	NULL
200	NULL
M	NULL
pervanadate	NULL
(	NULL
pV	NULL
)	NULL
.	NULL

After	NULL
cell	NULL
lysis	NULL
,	NULL
PLCy1	NULL
was	NULL
immunoprecipitated	NULL
.	NULL

Non-immune	NULL
rabbit	NULL
immunoglobulins	NULL
were	NULL
used	NULL
as	NULL
control	NULL
.	NULL

Samples	NULL
were	NULL
subjected	NULL
to	NULL
SDS/PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
an	NULL
anti-phosphotyrosine	NULL
antibody	NULL
(	NULL
@	NULL
)	NULL
.	NULL

(	NULL
)	NULL
PLCy1	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
*°S-labelled	NULL
cells	NULL
and	NULL
analysed	NULL
by	NULL
SDS/PAGE	NULL
.	NULL

,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
&	NULL
-69	NULL
>	NULL
«	NULL
eager	NULL
tames	NULL
<	NULL
*	NULL
t	NULL
seran	NULL
-	NULL
46	NULL
3	NULL
B	NULL
-	NULL
30	NULL
-	NULL
21	NULL
&	NULL
6	NULL
&	NULL
6	NULL
B08	NULL
``	NULL
90	NULL
“	NULL
s	NULL
F.	NULL
90V	NULL
L______	NULL
Basal	NULL
pV	NULL
Figure	NULL
7	NULL
-	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
pervanadate	NULL
in	NULL
CO45-negative	NULL
Jurkat	NULL
variants	NULL
Jurkat	NULL
cells	NULL
and	NULL
CD4S-negative	NULL
variants	NULL
were	NULL
stimulated	NULL
by	NULL
pervanadate	NULL
(	NULL
pV	NULL
;	NULL
200	NULL
M	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
was	NULL
revealed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

band	NULL
appeared	NULL
which	NULL
probably	NULL
corresponds	NULL
to	NULL
a	NULL
phosphotyrosine	NULL
form	NULL
of	NULL
PLCy1	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
pervanadate	NULL
and	NULL
anti-CD3	NULL
mAb	NULL
on	NULL
[	NULL
Ca**	NULL
]	NULL
,	NULL
were	NULL
equally	NULL
blocked	NULL
by	NULL
preincubation	NULL
with	NULL
PTK	NULL
inhibitors	NULL
such	NULL
as	NULL
staurosporine	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
,	NULL
genistein	NULL
(	NULL
100	NULL
4M	NULL
,	NULL
5	NULL
min	NULL
)	NULL
and	NULL
herbimycin	NULL
A	NULL
(	NULL
10	NULL
uM	NULL
,	NULL
18	NULL
h	NULL
)	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
observations	NULL
show	NULL
that	NULL
pervanadate	NULL
and	NULL
anti-CD3	NULL
mAb	NULL
regulate	NULL
[	NULL
Ca®**	NULL
]	NULL
,	NULL
by	NULL
different	NULL
mechanisms	NULL
that	NULL
both	NULL
imply	NULL
active	NULL
PTK	NULL
entities	NULL
.	NULL

55	NULL
Jurkat	NULL
cells	NULL
@	NULL
-	NULL
A	NULL
A	NULL
®	NULL
a	NULL
o	NULL
a	NULL
o	NULL
w	NULL
o	NULL
CD45-deficient	NULL
cells	NULL
No	NULL
on	NULL
Fluorescence	NULL
ratio	NULL
(	NULL
arbitrary	NULL
units	NULL
)	NULL
ho	NULL
©	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
Figure	NULL
8	NULL
-	NULL
Induction	NULL
of	NULL
Ca®*	NULL
influx	NULL
by	NULL
pervanadate	NULL
in	NULL
CD45-negative	NULL
Jurkat	NULL
variants	NULL
Jurkat	NULL
cells	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
and	NULL
CD4S5-negative	NULL
variants	NULL
(	NULL
closed	NULL
symbols	NULL
)	NULL
were	NULL
loaded	NULL
with	NULL
Indo-1	NULL
and	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
(	NULL
0.5	NULL
g/m	NULL
!	NULL
)	NULL

(	NULL
A	NULL
,	NULL
A	NULL
)	NULL
or	NULL
pervanadate	NULL
(	NULL
200	NULL
#	NULL
M	NULL
)	NULL
(	NULL
0	NULL
)	NULL
,	NULL
MM	NULL
)	NULL
.	NULL

Fluorescence	NULL
ratios	NULL
were	NULL
analysed	NULL
on	NULL
a	NULL
cell	NULL
sorter	NULL
.	NULL

Effect	NULL
of	NULL
pervanadate	NULL
on	NULL
a	NULL
CD45-negative	NULL
variant	NULL
of	NULL
Jurkat	NULL
cells	NULL
Because	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
phosphotyrosine	NULL
on	NULL
cellular	NULL
proteins	NULL
is	NULL
the	NULL
result	NULL
of	NULL
opposing	NULL
activities	NULL
of	NULL
PTKs	NULL
and	NULL
PTPases	NULL
and	NULL
considering	NULL
that	NULL
CD45	NULL
is	NULL
the	NULL
predominant	NULL
PTPase	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
T-cells	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
pervanadate	NULL
in	NULL
a	NULL
CD4S-deficient	NULL
variant	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

First	NULL
,	NULL
we	NULL
compared	NULL
tyrosine	NULL
phosphorylation	NULL
levels	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
the	NULL
CD45-negative	NULL
variant	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

On	NULL
unstimulated	NULL
variant	NULL
cells	NULL
we	NULL
noted	NULL
the	NULL
additional	NULL
presence	NULL
of	NULL
a	NULL
phosphotyrosine-containing	NULL
55	NULL
kDa	NULL
protein	NULL
and	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
67	NULL
kDa	NULL
protein	NULL
.	NULL

Stimulation	NULL
by	NULL
pervanadate	NULL
led	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
both	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
tyrosine-phosphorylated	NULL
protein	NULL
pattern	NULL
resulting	NULL
from	NULL
pervanadate	NULL
treatment	NULL
appeared	NULL
to	NULL
be	NULL
markedly	NULL
lower	NULL
in	NULL
the	NULL
CD4S5-negative	NULL
variant	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
parental	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
some	NULL
phosphotyrosine	NULL
proteins	NULL
were	NULL
missing	NULL
in	NULL
the	NULL
variant	NULL
(	NULL
arrowheads	NULL
)	NULL
which	NULL
could	NULL
correspond	NULL
to	NULL
specific	NULL
CD45	NULL
substrates	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
CD45	NULL
tyrosine	NULL
phosphatase	NULL
profoundly	NULL
altered	NULL
the	NULL
effect	NULL
that	NULL
pervanadate	NULL
exerts	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
substrates	NULL
.	NULL

We	NULL
next	NULL
analysed	NULL
Ca®**	NULL
fluxes	NULL
in	NULL
the	NULL
CD4S-negative	NULL
variant	NULL
(	NULL
Figure	NULL
8	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
[	NULL
22	NULL
]	NULL
,	NULL
these	NULL
variants	NULL
display	NULL
a	NULL
lower	NULL
response	NULL
to	NULL
TcR-CD3	NULL
stimulation	NULL
due	NULL
to	NULL
a	NULL
deficient	NULL
coupling	NULL
of	NULL
the	NULL
receptor	NULL
with	NULL
downstream	NULL
signalling	NULL
events	NULL
.	NULL

The	NULL
Ca**	NULL
response	NULL
to	NULL
pervanadate	NULL
was	NULL
completely	NULL
abolished	NULL
in	NULL
CD45-deficient	NULL
cells	NULL
even	NULL
though	NULL
a	NULL
slight	NULL
but	NULL
significant	NULL
response	NULL
was	NULL
still	NULL
observed	NULL
with	NULL
CD3	NULL
stimulation	NULL
.	NULL

Pervanadate	NULL
induces	NULL
c-fos	NULL
mRNA	NULL
accumulation	NULL
Transcription	NULL
of	NULL
the	NULL
early	NULL
gene	NULL
c-fos	NULL
was	NULL
investigated	NULL
by	NULL
Northern-blot	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
Figure	NULL
9	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
RNA	NULL
encoding	NULL
the	NULL
c-fos	NULL
product	NULL
largely	NULL
increased	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
PMA	NULL
.	NULL

Pervanadate	NULL
also	NULL
induced	NULL
c-fos	NULL
mRNA	NULL
,	NULL
but	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
.	NULL

No	NULL
synergistic	NULL
effect	NULL
was	NULL
observed	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
pervanadate	NULL
and	NULL
PMA	NULL
.	NULL

The	NULL
treatments	NULL
did	NULL
not	NULL
affect	NULL
actin	NULL
mRNA	NULL
levels	NULL
.	NULL

We	NULL
then	NULL
analysed	NULL
expression	NULL
of	NULL
the	NULL
c-fos	NULL
gene	NULL
by	NULL
using	NULL
a	NULL
gene-reporter	NULL
technique	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
carrying	NULL
a	NULL
luciferase	NULL
indicator	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

Activation	NULL
of	NULL
this	NULL
promoter	NULL
results	NULL
in	NULL
luciferase	NULL
production	NULL
.	NULL

Luciferase	NULL
Regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
by	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
169	NULL
%	NULL
D	NULL
W	NULL
T	NULL
UW	NULL
D	NULL
~c~	NULL
Figure	NULL
9	NULL
-	NULL
Northern-biot	NULL
analysis	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
200	NULL
,	NULL
100	NULL
and	NULL
50	NULL
«	NULL
M	NULL
pervanadate	NULL
(	NULL
pV	NULL
)	NULL
or	NULL
50	NULL
ng/ml	NULL
PMA	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
RNA	NULL
blots	NULL
were	NULL
prepared	NULL
from	NULL
equalized	NULL
samples	NULL
(	NULL
15	NULL
g	NULL
)	NULL
and	NULL
separately	NULL
hybridized	NULL
with	NULL
probes	NULL
specific	NULL
for	NULL
c-fos	NULL
or	NULL
actin	NULL
.	NULL

Table	NULL
2	NULL
-	NULL
Activation	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
by	NULL
pervanadate	NULL
and	NULL
PMA	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
with	NULL
a	NULL
c-fos	NULL
promoter-luciferase	NULL
gene	NULL
construct	NULL
and	NULL
grown	NULL
for	NULL
72	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
pervanadate	NULL
(	NULL
200	NULL
M	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
18	NULL
h.	NULL
Cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
repeated	NULL
freezing	NULL
and	NULL
thawing	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
on	NULL
10	NULL
q	NULL
of	NULL
cell	NULL
extracts	NULL
and	NULL
was	NULL
defined	NULL
in	NULL
relative	NULL
luminescence	NULL
light	NULL
units	NULL
.	NULL

The	NULL
increases	NULL
in	NULL
activity	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
parentheses	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Luciferase	NULL
activity	NULL
Conditions	NULL
(	NULL
units/10	NULL
g	NULL
of	NULL
protein	NULL
)	NULL
Basal	NULL
9.8	NULL
PMA	NULL
36.3	NULL
(	NULL
3.7	NULL
)	NULL
Pervanadate	NULL
30.98	NULL
(	NULL
3.1	NULL
)	NULL
Pervanadate	NULL
+	NULL
PMA	NULL
169.2	NULL
(	NULL
17	NULL
)	NULL
activity	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
photon	NULL
counting	NULL
,	NULL
is	NULL
proportional	NULL
to	NULL
luciferase	NULL
concentration	NULL
and	NULL
therefore	NULL
to	NULL
c-fos	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
results	NULL
of	NULL
such	NULL
an	NULL
experiment	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

PMA	NULL
(	NULL
a	NULL
)	NULL
C	NULL
€	NULL
200	NULL
S	NULL
-	NULL
q	NULL
&	NULL
100	NULL
xvi	NULL
MM	NULL
3	NULL
3	NULL
T	NULL
T	NULL
``	NULL
~~~	NULL
u	NULL
T	NULL
0	NULL
u	NULL
100	NULL
150	NULL
200	NULL
£	NULL
&	NULL
g	NULL
(	NULL
c	NULL
)	NULL
®	NULL
8	NULL
200	NULL
4	NULL
!	NULL

z	NULL
,	NULL
1	NULL
f	NULL
5	NULL
100	NULL
1	NULL
Mu	NULL
,	NULL
”	NULL
i	NULL
.	NULL

A.	NULL
T	NULL
mj	NULL
T	NULL
U	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
Cell	NULL
number	NULL
Figure	NULL
10	NULL
-	NULL
Pervanadate	NULL
induction	NULL
of	NULL
CD69	NULL
expression	NULL
and	NULL
pervanadate	NULL
stimulated	NULL
to	NULL
the	NULL
same	NULL
extent	NULL
(	NULL
3-4-fold	NULL
)	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

Maximal	NULL
stimulation	NULL
was	NULL
obtained	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
pervanadate	NULL
and	NULL
PMA	NULL
(	NULL
17-fold	NULL
)	NULL
.	NULL

The	NULL
compounds	NULL
thus	NULL
acted	NULL
at	NULL
a	NULL
transcriptional	NULL
level	NULL
on	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

The	NULL
synergy	NULL
between	NULL
PMA	NULL
and	NULL
pervanadate	NULL
on	NULL
c-fos	NULL
promoter	NULL
was	NULL
not	NULL
observed	NULL
on	NULL
c-fos	NULL
mRNA	NULL
levels	NULL
.	NULL

The	NULL
difference	NULL
could	NULL
be	NULL
attributed	NULL
to	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
experiments	NULL
:	NULL
luciferase	NULL
assays	NULL
were	NULL
performed	NULL
after	NULL
18	NULL
h	NULL
of	NULL
stimulation	NULL
to	NULL
allow	NULL
a	NULL
sufficient	NULL
accumulation	NULL
of	NULL
luciferase	NULL
activity	NULL
whereas	NULL
cells	NULL
were	NULL
activated	NULL
for	NULL
only	NULL
30	NULL
min	NULL
for	NULL
Northern-blot	NULL
analysis	NULL
.	NULL

Induction	NULL
of	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
activation	NULL
antigen	NULL
CD69	NULL
by	NULL
pervanadate	NULL
Stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
results	NULL
in	NULL
expression	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
genes	NULL
within	NULL
a	NULL
long	NULL
time	NULL
frame	NULL
[	NULL
42	NULL
]	NULL
.	NULL

One	NULL
such	NULL
gene	NULL
encodes	NULL
the	NULL
early-activation	NULL
antigen	NULL
CD69	NULL
,	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
induced	NULL
within	NULL
hours	NULL
of	NULL
TcR-CD3	NULL
stimulation	NULL
[	NULL
43	NULL
]	NULL
.	NULL

Although	NULL
the	NULL
function	NULL
of	NULL
CD69	NULL
in	NULL
T-cell	NULL
activation	NULL
is	NULL
not	NULL
well	NULL
understood	NULL
,	NULL
this	NULL
antigen	NULL
is	NULL
a	NULL
good	NULL
marker	NULL
of	NULL
distal	NULL
signal-transduction	NULL
events	NULL
.	NULL

Flow-cytometry	NULL
analysis	NULL
revealed	NULL
that	NULL
CD69	NULL
labelling	NULL
on	NULL
unstimulated	NULL
cells	NULL
(	NULL
Figure	NULL
10a	NULL
)	NULL
displayed	NULL
a	NULL
fluorescence	NULL
intensity	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
when	NULL
an	NULL
irrelevant	NULL
mAb	NULL
is	NULL
used	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
pervanadate	NULL
resulted	NULL
in	NULL
only	NULL
a	NULL
marginal	NULL
increase	NULL
in	NULL
CD69	NULL
levels	NULL
(	NULL
Figure	NULL
10b	NULL
)	NULL
.	NULL

PMA	NULL
was	NULL
more	NULL
efficient	NULL
at	NULL
inducing	NULL
CD69	NULL
expression	NULL
(	NULL
Figure	NULL
10¢	NULL
)	NULL
and	NULL
its	NULL
action	NULL
was	NULL
synergized	NULL
when	NULL
used	NULL
in	NULL
combination	NULL
with	NULL
pervanadate	NULL
(	NULL
Figure	NULL
10d	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
CD69	NULL
by	NULL
pervanadate	NULL
was	NULL
blocked	NULL
by	NULL
herbimycin	NULL
A	NULL
(	NULL
10	NULL
4M	NULL
)	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Pervanadate	NULL
stimulates	NULL
IL-2	NULL
production	NULL
and	NULL
surface	NULL
expression	NULL
of	NULL
IL-2	NULL
receptor	NULL
«	NULL
-chain	NULL
One	NULL
of	NULL
the	NULL
most	NULL
commonly	NULL
used	NULL
criteria	NULL
to	NULL
assess	NULL
late	NULL
T-cell-activation	NULL
events	NULL
is	NULL
production	NULL
of	NULL
the	NULL
lymphokine	NULL
IL-2	NULL
[	NULL
44	NULL
]	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
,	NULL
induction	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
requires	NULL
engagement	NULL
of	NULL
the	NULL
T-cell-antigen	NULL
receptor	NULL
by	NULL
agonist	NULL
mAb	NULL
(	NULL
gen-erally	NULL
anti-CD3	NULL
mAb	NULL
)	NULL
together	NULL
with	NULL
a	NULL
second	NULL
signal	NULL
provided	NULL
by	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
TcR-CD3	NULL
complex	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
a	NULL
Ca®*	NULL
ionophore	NULL
A23187	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
,	NULL
co-stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
Ca**	NULL
ionophore	NULL
and	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
{	NULL
d	NULL
)	NULL
1	NULL
``	NULL
a	NULL
100	NULL
w	NULL
o	NULL
a	NULL
ie	NULL
rate	NULL
Aide	NULL
?	NULL

°	NULL
T	NULL
U	NULL
T	NULL
U	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
Cell	NULL
number	NULL
Cells	NULL
were	NULL
stimulated	NULL
or	NULL
not	NULL
(	NULL
@	NULL
)	NULL
for	NULL
5	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
by	NULL
pervanadate	NULL
(	NULL
200	NULL
M	NULL
)	NULL
(	NULL
b	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

(	NULL
e	NULL
)	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
effectors	NULL
(	NULL
d	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
first	NULL
incubated	NULL
with	NULL
an	NULL
anti-CD69	NULL
mAb	NULL
,	NULL
and	NULL
then	NULL
with	NULL
an	NULL
FITC-conjugated	NULL
secondary	NULL
antibody	NULL
.	NULL

Flow-cytometry	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
a	NULL
cell	NULL
sorter	NULL
.	NULL

170	NULL
V.	NULL
Imbert	NULL
and	NULL
others	NULL
Table	NULL
3	NULL
After	NULL
incubation	NULL
with	NULL
various	NULL
effectors	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
IL-2	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
e.l.i.s.a	NULL
.	NULL

Effectors	NULL
were	NULL
used	NULL
at	NULL
the	NULL
following	NULL
concentrations	NULL
:	NULL
PMA	NULL
,	NULL
10	NULL
ng/ml	NULL
;	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
1	NULL
g/m	NULL
}	NULL
;	NULL
Ca**	NULL
ionophore	NULL
A23187	NULL
,	NULL
0.2	NULL
M.	NULL
In	NULL
the	NULL
second	NULL
experiment	NULL
,	NULL
pervanadate	NULL
was	NULL
used	NULL
at	NULL
200	NULL
M.	NULL
Data	NULL
are	NULL
means	NULL
+	NULL
S.D	NULL
.	NULL

of	NULL
three	NULL
determinations	NULL
.	NULL

Induction	NULL
of	NULL
IL-2	NULL
production	NULL
by	NULL
pervanadate	NULL
Experiment	NULL
1	NULL
Experiment	NULL
2	NULL
[	NULL
IL-2	NULL
]	NULL
Conditions	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

Conditions	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

Basal	NULL
0.003	NULL
Basal	NULL
0.021	NULL
A23187	NULL
+	NULL
PMA	NULL
35	NULL
+2	NULL
A23187	NULL
+	NULL
PMA	NULL
13.3	NULL
+0.013	NULL
PMA	NULL
0.181	NULL
+0.0015	NULL
Pervanadate	NULL
215	NULL
+0.35	NULL
Pervanadate	NULL
30	NULL
+2	NULL
CO3	NULL
0	NULL
(	NULL
200	NULL
M	NULL
)	NULL
+	NULL
PMA	NULL
Pervanadate	NULL
16	NULL
+0.02	NULL
Pervanadate	NULL
+	NULL
CD3	NULL
4.92	NULL
+0.34	NULL
(	NULL
100	NULL
M	NULL
)	NULL
+	NULL
PMA	NULL
Pervanadate	NULL
10.92	NULL
+2.08	NULL
Pervanadate	NULL
+	NULL
PMA	NULL
11.32	NULL
+03	NULL
(	NULL
50	NULL
M	NULL
)	NULL
+	NULL
PMA	NULL
Control	NULL
+	NULL
PMA	NULL
0.224	NULL
+	NULL
0.02	NULL
Pervanadate	NULL
+	NULL
CD3	NULL
16+0.23	NULL
+	NULL
PMA	NULL
Pervanadate	NULL
6.98	NULL
+	NULL
0.99	NULL
CD3	NULL
+	NULL
PMA	NULL
9.21	NULL
£0.25	NULL
(	NULL
200	NULL
M	NULL
)	NULL
Pervanadate	NULL
1.01	NULL
£0.05	NULL
(	NULL
100	NULL
gM	NULL
)	NULL
Pervanadate	NULL
0.349	NULL
+0.033	NULL
(	NULL
50	NULL
wM	NULL
)	NULL
Controt	NULL
0.002	NULL
Table	NULL
4	NULL
-	NULL
Induction	NULL
of	NULL
surface	NULL
expression	NULL
of	NULL
IL-2	NULL
receptor	NULL
by	NULL
pervanadate	NULL
and	NULL
PMA	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
18	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
pervanadate	NULL
{	NULL
200	NULL
M	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
first	NULL
incubated	NULL
with	NULL
an	NULL
anti-CD25	NULL
mAb	NULL
,	NULL
and	NULL
then	NULL
with	NULL
an	NULL
FITC-conjugated	NULL
secondary	NULL
antibody	NULL
.	NULL

Flow-cytometry	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
a	NULL
cell	NULL
sorter	NULL
.	NULL

These	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Percentage	NULL
of	NULL
cells	NULL
expressing	NULL
Conditions	NULL
CD25	NULL
antigen	NULL
Basal	NULL
0	NULL
Pervanadate	NULL
9	NULL
PMA	NULL
22	NULL
Pervanadate	NULL
+	NULL
PMA	NULL
45	NULL
PMA	NULL
for	NULL
18	NULL
h	NULL
led	NULL
to	NULL
maximal	NULL
secretion	NULL
of	NULL
IL-2	NULL
(	NULL
35	NULL
ng/ml	NULL
)	NULL
.	NULL

Pervanadate	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
PMA	NULL
induced	NULL
a	NULL
dose-dependent	NULL
IL-2	NULL
production	NULL
.	NULL

It	NULL
is	NULL
notable	NULL
that	NULL
pervanadate	NULL
,	NULL
when	NULL
used	NULL
alone	NULL
,	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
IL-2	NULL
secretion	NULL
,	NULL
although	NULL
at	NULL
a	NULL
low	NULL
level	NULL
,	NULL
whereas	NULL
PMA	NULL
alone	NULL
failed	NULL
to	NULL
do	NULL
so	NULL
.	NULL

In	NULL
a	NULL
second	NULL
experiment	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
effect	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
pervanadate	NULL
on	NULL
IL-2	NULL
production	NULL
.	NULL

Anti-CD3	NULL
mAb	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
,	NULL
whereas	NULL
pervanadate	NULL
alone	NULL
(	NULL
200	NULL
«	NULL
M	NULL
)	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
IL-2	NULL
production	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
.	NULL

When	NULL
added	NULL
together	NULL
,	NULL
the	NULL
two	NULL
compounds	NULL
had	NULL
a	NULL
synergistic	NULL
effect	NULL
(	NULL
5	NULL
ng/ml	NULL
)	NULL
.	NULL

Co-stimulation	NULL
of	NULL
cells	NULL
with	NULL
either	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
PMA	NULL
or	NULL
pervanadate	NULL
and	NULL
PMA	NULL
resulted	NULL
in	NULL
similar	NULL
levels	NULL
of	NULL
IL-2	NULL
secretion	NULL
(	NULL
respectively	NULL
9	NULL
and	NULL
11	NULL
ng/ml	NULL
)	NULL
.	NULL

Higher	NULL
IL-2	NULL
production	NULL
was	NULL
obtained	NULL
with	NULL
the	NULL
combination	NULL
anti-CD3	NULL
+	NULL
PMA	NULL
+pervanadate	NULL
(	NULL
16	NULL
ng/ml	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
pervanadate	NULL
induced	NULL
IL-2	NULL
production	NULL
alone	NULL
or	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
.	NULL

ti	NULL
i	NULL
ut	NULL
ol	NULL
bu	NULL
B	NULL
i	NULL
bn	NULL
-	NULL
*=	NULL
wall	NULL
wl	NULL
wy	NULL
oul	NULL
we	NULL
wil	NULL
Free	NULL
probe	NULL
Figure	NULL
11	NULL
-	NULL
Pervanadate	NULL
induction	NULL
of	NULL
NF-xB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
Jurkat	NULL
T-ceils	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
control	NULL
cells	NULL
or	NULL
cells	NULL
stimulated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
Ca	NULL
``	NULL
*	NULL
ionophore	NULL
A23187	NULL
(	NULL
0.5	NULL
M	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
different	NULL
concentrations	NULL
of	NULL
pervanadate	NULL
(	NULL
pV	NULL
)	NULL
.	NULL

An	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
radiolabelled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
NF-xB-binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
unbound	NULL
oligonucleotide	NULL
(	NULL
free	NULL
probe	NULL
)	NULL
and	NULL
the	NULL
retarded	NULL
DNA-protein	NULL
complex	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

We	NULL
then	NULL
analysed	NULL
another	NULL
late	NULL
event	NULL
of	NULL
T-cell	NULL
activation	NULL
:	NULL
expression	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
«	NULL
-chain	NULL
(	NULL
CD25	NULL
)	NULL
[	NULL
45	NULL
]	NULL
.	NULL

The	NULL
results	NULL
of	NULL
a	NULL
flow	NULL
cytometry	NULL
analysis	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
4	NULL
.	NULL

No	NULL
IL-2	NULL
receptor	NULL
could	NULL
be	NULL
detected	NULL
on	NULL
unstimulated	NULL
cells	NULL
.	NULL

Stimulation	NULL
with	NULL
pervanadate	NULL
induced	NULL
a	NULL
small	NULL
expression	NULL
of	NULL
CD25	NULL
(	NULL
9	NULL
%	NULL
of	NULL
positive	NULL
cells	NULL
)	NULL
.	NULL

With	NULL
PMA	NULL
,	NULL
levels	NULL
of	NULL
CD25	NULL
expression	NULL
were	NULL
higher	NULL
(	NULL
22	NULL
%	NULL
)	NULL
.	NULL

Maximal	NULL
induction	NULL
of	NULL
CD25	NULL
expression	NULL
was	NULL
produced	NULL
by	NULL
co-stimulation	NULL
with	NULL
pervanadate	NULL
and	NULL
PMA	NULL
(	NULL
45	NULL
%	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
inhibition	NULL
of	NULL
PTPases	NULL
by	NULL
pervanadate	NULL
induced	NULL
several	NULL
late	NULL
events	NULL
of	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
.	NULL

Pervanadate	NULL
activates	NULL
NF-xB	NULL
We	NULL
finally	NULL
investigated	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
one	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
[	NULL
46,47	NULL
]	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
heterodimer	NULL
composed	NULL
of	NULL
two	NULL
proteins	NULL
,	NULL
p50	NULL
and	NULL
p65	NULL
[	NULL
48,49	NULL
]	NULL
.	NULL

In	NULL
unstimulated	NULL
cells	NULL
,	NULL
with	NULL
the	NULL
notable	NULL
exception	NULL
of	NULL
B-cells	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
retained	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
an	NULL
inactive	NULL
complex	NULL
by	NULL
an	NULL
inhibitory	NULL
protein	NULL
,	NULL
IxB	NULL
,	NULL
and	NULL
can	NULL
not	NULL
bind	NULL
DNA	NULL
[	NULL
50,51	NULL
]	NULL
.	NULL

In	NULL
response	NULL
to	NULL
various	NULL
stimuli	NULL
,	NULL
the	NULL
IxB-NF-	NULL
«	NULL
B	NULL
complex	NULL
dissociates	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
detected	NULL
in	NULL
the	NULL
nucleus	NULL
[	NULL
52	NULL
]	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
various	NULL
effectors	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
11	NULL
,	NULL
a	NULL
1	NULL
h	NULL
stimulation	NULL
with	NULL
A23187	NULL
plus	NULL
PMA	NULL
resulted	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
two	NULL
retarded	NULL
bands	NULL
corresponding	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Stimulation	NULL
with	NULL
PMA	NULL
alone	NULL
also	NULL
resulted	NULL
in	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
.	NULL

Similarly	NULL
,	NULL
pervanadate	NULL
could	NULL
activate	NULL
NF-KB	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
and	NULL
could	NULL
potentiate	NULL
Regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
by	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
171	NULL
the	NULL
effect	NULL
of	NULL
PMA	NULL
.	NULL

Control	NULL
stimulation	NULL
containing	NULL
only	NULL
H	NULL
,	NULL
O	NULL
,	NULL
and	NULL
catalase	NULL
,	NULL
without	NULL
vanadate	NULL
,	NULL
failed	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
requires	NULL
generation	NULL
of	NULL
pervanadate	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
was	NULL
insensitive	NULL
to	NULL
addition	NULL
of	NULL
EGTA	NULL
to	NULL
the	NULL
medium	NULL
at	NULL
concentrations	NULL
that	NULL
blocked	NULL
pervanadate-induced	NULL
Ca**	NULL
fluxes	NULL
.	NULL

We	NULL
verified	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
was	NULL
insensitive	NULL
to	NULL
H7	NULL
,	NULL
a	NULL
PKC	NULL
inhibitor	NULL
,	NULL
which	NULL
prevented	NULL
PMA-induced	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
abolished	NULL
by	NULL
herbimycin	NULL
A	NULL
,	NULL
a	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
may	NULL
have	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
a	NULL
pathway	NULL
that	NULL
excludes	NULL
the	NULL
classical	NULL
PKC-dependent	NULL
regulation	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
have	NULL
studied	NULL
the	NULL
role	NULL
of	NULL
PTPases	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
,	NULL
by	NULL
using	NULL
a	NULL
powerful	NULL
inhibitor	NULL
of	NULL
this	NULL
family	NULL
of	NULL
enzymes	NULL
(	NULL
pervanadate	NULL
)	NULL
.	NULL

Pervanadate	NULL
appeared	NULL
to	NULL
have	NULL
stimulatory	NULL
effects	NULL
on	NULL
various	NULL
cell	NULL
types	NULL
including	NULL
platelets	NULL
,	NULL
peripheral	NULL
T-cells	NULL
,	NULL
neutrophils	NULL
,	NULL
adipocytes	NULL
and	NULL
tumour	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HL60	NULL
and	NULL
CHO	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
pervanadate	NULL
acts	NULL
by	NULL
increasing	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
proteins	NULL
(	NULL
26-32	NULL
,	NULL
53-55	NULL
]	NULL
.	NULL

We	NULL
first	NULL
verified	NULL
that	NULL
pervanadate	NULL
inhibited	NULL
total	NULL
Jurkat	NULL
cellular	NULL
PTPase	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
that	NULL
of	NULL
immunoprecipitated	NULL
CD45	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
PTPases	NULL
are	NULL
negative	NULL
regulators	NULL
of	NULL
T-cell	NULL
activation	NULL
processes	NULL
,	NULL
as	NULL
their	NULL
inhibition	NULL
by	NULL
pervanadate	NULL
induced	NULL
early	NULL
,	NULL
as	NULL
well	NULL
as	NULL
late	NULL
,	NULL
events	NULL
of	NULL
Jurkat	NULL
activation	NULL
.	NULL

The	NULL
earliest	NULL
detectable	NULL
effect	NULL
of	NULL
pervanadate	NULL
stimulation	NULL
was	NULL
an	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
cellular	NULL
substrates	NULL
.	NULL

Pervanadate	NULL
appeared	NULL
to	NULL
be	NULL
the	NULL
most	NULL
powerful	NULL
promoter	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
so	NULL
far	NULL
tested	NULL
in	NULL
human	NULL
T-cells	NULL
,	NULL
allowing	NULL
the	NULL
visualization	NULL
of	NULL
numerous	NULL
additional	NULL
PTK/PTPase	NULL
substrates	NULL
,	NULL
which	NULL
were	NULL
not	NULL
observed	NULL
with	NULL
TeR-CD3	NULL
stimulation	NULL
.	NULL

An	NULL
earlier	NULL
study	NULL
[	NULL
56	NULL
]	NULL
has	NULL
shown	NULL
that	NULL
inhibition	NULL
of	NULL
T-cell	NULL
PTPases	NULL
by	NULL
phenylarsine	NULL
oxide	NULL
enhanced	NULL
TcR-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
proteins	NULL
.	NULL

However	NULL
,	NULL
distal	NULL
events	NULL
could	NULL
not	NULL
be	NULL
investigated	NULL
in	NULL
that	NULL
study	NULL
owing	NULL
to	NULL
the	NULL
toxic	NULL
effect	NULL
of	NULL
phenylarsine	NULL
oxide	NULL
.	NULL

The	NULL
rapid	NULL
and	NULL
extensive	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
Jurkat	NULL
cells	NULL
demonstrates	NULL
that	NULL
PTPases	NULL
must	NULL
normally	NULL
exert	NULL
a	NULL
tight	NULL
control	NULL
over	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
T-lymphocytes	NULL
.	NULL

It	NULL
is	NULL
not	NULL
yet	NULL
known	NULL
whether	NULL
the	NULL
action	NULL
of	NULL
pervanadate	NULL
results	NULL
from	NULL
inhibition	NULL
of	NULL
PTPases	NULL
that	NULL
oppose	NULL
constitutively	NULL
active	NULL
PTK	NULL
or	NULL
indirect	NULL
stimulation	NULL
of	NULL
PTK	NULL
through	NULL
unrestrained	NULL
autophosphorylation	NULL
.	NULL

In	NULL
the	NULL
first	NULL
situation	NULL
,	NULL
the	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
results	NULL
from	NULL
the	NULL
accumulation	NULL
of	NULL
phosphate	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dephosphorylation	NULL
reactions	NULL
without	NULL
any	NULL
variation	NULL
in	NULL
kinase	NULL
activities	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
second	NULL
situation	NULL
implies	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
specific	NULL
activity	NULL
of	NULL
the	NULL
kinases	NULL
.	NULL

This	NULL
seems	NULL
to	NULL
be	NULL
the	NULL
case	NULL
in	NULL
our	NULL
model	NULL
,	NULL
at	NULL
least	NULL
for	NULL
the	NULL
src-like	NULL
PTKs	NULL
Ick	NULL
and	NULL
fyn	NULL
,	NULL
the	NULL
activities	NULL
of	NULL
which	NULL
are	NULL
stimulated	NULL
by	NULL
pervanadate	NULL
.	NULL

This	NULL
stimulation	NULL
is	NULL
probably	NULL
involved	NULL
in	NULL
the	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jurkat	NULL
cellular	NULL
proteins	NULL
induced	NULL
by	NULL
pervanadate	NULL
.	NULL

Our	NULL
results	NULL
,	NULL
obtained	NULL
on	NULL
intact	NULL
cells	NULL
,	NULL
thus	NULL
suggest	NULL
that	NULL
certain	NULL
PTPases	NULL
exert	NULL
a	NULL
negative	NULL
effect	NULL
on	NULL
Ick	NULL
and	NULL
fyn	NULL
activities	NULL
.	NULL

One	NULL
attractive	NULL
candidate	NULL
is	NULL
CD45	NULL
,	NULL
the	NULL
major	NULL
transmembrane	NULL
PTPase	NULL
expressed	NULL
in	NULL
T-cells	NULL
.	NULL

However	NULL
,	NULL
CD45	NULL
has	NULL
been	NULL
shown	NULL
,	NULL
at	NULL
least	NULL
in	NULL
vitro	NULL
,	NULL
to	NULL
activate	NULL
Ick	NULL
and	NULL
fyn	NULL
through	NULL
dephosphorylation	NULL
of	NULL
an	NULL
inhibitory	NULL
C-terminal	NULL
phosphotyrosine	NULL
sesidue	NULL
(	NULL
Tyr-505	NULL
and	NULL
Tyr-531	NULL
for	NULL
Ick	NULL
and	NULL
fyn	NULL
respectively	NULL
)	NULL
[	NULL
33-35	NULL
}	NULL
.	NULL

According	NULL
to	NULL
this	NULL
model	NULL
,	NULL
inhibition	NULL
of	NULL
CD45	NULL
by	NULL
pervanadate	NULL
would	NULL
rather	NULL
inhibit	NULL
Ick	NULL
and	NULL
fyn	NULL
.	NULL

Never	NULL
theless	NULL
,	NULL
two	NULL
reports	NULL
have	NULL
also	NULL
described	NULL
an	NULL
increased	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
of	NULL
Ick	NULL
in	NULL
CD4S-negative	NULL
variants	NULL
of	NULL
HPB	NULL
ALL	NULL
[	NULL
57	NULL
]	NULL
and	NULL
Jurkat	NULL
cells	NULL
[	NULL
58	NULL
]	NULL
,	NULL
indicating	NULL
that	NULL
CD45	NULL
could	NULL
negatively	NULL
regulate	NULL
Ick	NULL
.	NULL

Along	NULL
the	NULL
same	NULL
line	NULL
,	NULL
we	NULL
also	NULL
measured	NULL
a	NULL
higher	NULL
activity	NULL
for	NULL
Ick	NULL
and	NULL
fyn	NULL
in	NULL
our	NULL
CD4S-negative	NULL
variants	NULL
(	NULL
V.	NULL
Imbert	NULL
and	NULL
J.-F.	NULL
Peyron	NULL
,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
kinases	NULL
is	NULL
thus	NULL
likely	NULL
to	NULL
be	NULL
more	NULL
complex	NULL
than	NULL
the	NULL
simplistic	NULL
control	NULL
of	NULL
the	NULL
phosphorylation	NULL
status	NULL
of	NULL
Tyr-505	NULL
and	NULL
Tyr-531	NULL
.	NULL

It	NULL
is	NULL
more	NULL
likely	NULL
that	NULL
several	NULL
PTPases	NULL
,	NULL
including	NULL
CD45	NULL
,	NULL
with	NULL
possibly	NULL
opposite	NULL
effects	NULL
,	NULL
act	NULL
on	NULL
the	NULL
kinases	NULL
through	NULL
modulation	NULL
of	NULL
different	NULL
tyrosine-phosphorylation	NULL
sites	NULL
.	NULL

The	NULL
role	NULL
of	NULL
individual	NULL
PTPases	NULL
such	NULL
as	NULL
CD45	NULL
in	NULL
this	NULL
response	NULL
remains	NULL
to	NULL
be	NULL
clarified	NULL
.	NULL

A	NULL
direct	NULL
stimulatory	NULL
effect	NULL
of	NULL
pervanadate	NULL
on	NULL
tyrosine	NULL
kinases	NULL
can	NULL
be	NULL
ruled	NULL
out	NULL
,	NULL
as	NULL
we	NULL
did	NULL
not	NULL
observe	NULL
any	NULL
increase	NULL
in	NULL
kinase	NULL
activity	NULL
of	NULL
purified	NULL
Ick	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
pervanadate	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
inactive	NULL
on	NULL
insulin	NULL
and	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptors	NULL
bearing	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
[	NULL
27,32	NULL
]	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
cell	NULL
stimulation	NULL
with	NULL
pervanadate	NULL
resulted	NULL
in	NULL
an	NULL
increased	NULL
intracellular	NULL
Ca**	NULL
concentration	NULL
and	NULL
we	NULL
showed	NULL
that	NULL
it	NULL
was	NULL
due	NULL
to	NULL
entry	NULL
of	NULL
Ca®*	NULL
ions	NULL
from	NULL
the	NULL
extracellular	NULL
medium	NULL
.	NULL

The	NULL
response	NULL
was	NULL
blocked	NULL
by	NULL
PTK	NULL
inhibitors	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
ruling	NULL
out	NULL
a	NULL
trivial	NULL
inhibition	NULL
of	NULL
a	NULL
Ca**	NULL
ATPase	NULL
by	NULL
pervanadate	NULL
.	NULL

The	NULL
Ca**	NULL
response	NULL
induced	NULL
by	NULL
pervanadate	NULL
appeared	NULL
to	NULL
be	NULL
different	NULL
from	NULL
that	NULL
induced	NULL
by	NULL
anti-CD3	NULL
mAb	NULL
which	NULL
triggered	NULL
both	NULL
a	NULL
mobilization	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
stores	NULL
and	NULL
an	NULL
influx	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
pervanadate	NULL
may	NULL
be	NULL
independent	NULL
of	NULL
IP	NULL
,	NULL
production	NULL
and	NULL
PLCy1	NULL
phosphorylation	NULL
but	NULL
may	NULL
instead	NULL
be	NULL
mediated	NULL
by	NULL
direct	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
Ca**	NULL
channel	NULL
or	NULL
of	NULL
a	NULL
channel-regulatory	NULL
molecule	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
hypothesis	NULL
,	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
that	NULL
T-cells	NULL
transfected	NULL
with	NULL
the	NULL
constitutive	NULL
PTK	NULL
v-src	NULL
displayed	NULL
a	NULL
higher	NULL
Ca®*	NULL
baseline	NULL
and	NULL
a	NULL
higher	NULL
Ca®**	NULL
response	NULL
to	NULL
T-cell	NULL
receptor	NULL
stimulation	NULL
,	NULL
whereas	NULL
IP	NULL
,	NULL
levels	NULL
were	NULL
not	NULL
affected	NULL
[	NULL
59	NULL
]	NULL
.	NULL

However	NULL
,	NULL
pervanadate	NULL
did	NULL
stimulate	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLCy1	NULL
,	NULL
even	NULL
though	NULL
it	NULL
failed	NULL
to	NULL
induce	NULL
Ca**	NULL
release	NULL
from	NULL
internal	NULL
stores	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLCy1	NULL
is	NULL
not	NULL
sufficient	NULL
by	NULL
itself	NULL
to	NULL
activate	NULL
the	NULL
enzyme	NULL
.	NULL

PLCy1	NULL
activation	NULL
seems	NULL
to	NULL
necessitate	NULL
TcR-CD3	NULL
aggregation	NULL
which	NULL
pervanadate	NULL
may	NULL
be	NULL
unable	NULL
to	NULL
induce	NULL
.	NULL

Looking	NULL
to	NULL
more	NULL
distal	NULL
events	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
pervanadate	NULL
as	NULL
well	NULL
as	NULL
PMA	NULL
were	NULL
able	NULL
to	NULL
induce	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
by	NULL
acting	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
at	NULL
a	NULL
transcriptional	NULL
level	NULL
.	NULL

Pervanadate	NULL
also	NULL
triggered	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
two	NULL
activation	NULL
markers	NULL
,	NULL
CD69	NULL
and	NULL
IL-2	NULL
receptor	NULL
«	NULL
-chain	NULL
(	NULL
CD25	NULL
)	NULL
,	NULL
and	NULL
this	NULL
effect	NULL
was	NULL
potentiated	NULL
by	NULL
PMA	NULL
.	NULL

Secretion	NULL
of	NULL
IL-2	NULL
appears	NULL
to	NULL
be	NULL
an	NULL
important	NULL
distal	NULL
marker	NULL
of	NULL
cell	NULL
activation	NULL
.	NULL

IL-2	NULL
production	NULL
by	NULL
Jurkat	NULL
cells	NULL
requires	NULL
the	NULL
combination	NULL
of	NULL
two	NULL
types	NULL
of	NULL
stimuli	NULL
[	NULL
60	NULL
]	NULL
.	NULL

Whereas	NULL
one	NULL
signal	NULL
is	NULL
produced	NULL
by	NULL
triggering	NULL
the	NULL
T-cell	NULL
receptor	NULL
,	NULL
i.e	NULL
.	NULL

with	NULL
anti-CD3	NULL
mAb	NULL
or	NULL
by	NULL
the	NULL
use	NULL
of	NULL
a	NULL
Ca**	NULL
ionophore	NULL
,	NULL
the	NULL
other	NULL
is	NULL
provided	NULL
by	NULL
the	NULL
phorbol	NULL
ester	NULL
,	NULL
PMA	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
pervanadate	NULL
was	NULL
able	NULL
by	NULL
itself	NULL
to	NULL
induce	NULL
IL-2	NULL
production	NULL
,	NULL
although	NULL
at	NULL
a	NULL
low	NULL
level	NULL
.	NULL

Yet	NULL
,	NULL
when	NULL
used	NULL
in	NULL
combination	NULL
with	NULL
either	NULL
anti-CD3	NULL
mAb	NULL
or	NULL
PMA	NULL
,	NULL
its	NULL
effect	NULL
was	NULL
amplified	NULL
and	NULL
produced	NULL
maximal	NULL
levels	NULL
of	NULL
IL-2	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
sufficient	NULL
per	NULL
se	NULL
to	NULL
initiate	NULL
a	NULL
complete	NULL
activation	NULL
process	NULL
.	NULL

However	NULL
,	NULL
alternative	NULL
pathways	NULL
,	NULL
for	NULL
instance	NULL
mimicked	NULL
by	NULL
PMA	NULL
,	NULL
are	NULL
required	NULL
to	NULL
amplify	NULL
the	NULL
response	NULL
.	NULL

Pervanadate	NULL
was	NULL
found	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
one	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
[	NULL
46,61	NULL
]	NULL
.	NULL

The	NULL
effect	NULL
required	NULL
generation	NULL
of	NULL
pervanadate	NULL
and	NULL
was	NULL
not	NULL
due	NULL
to	NULL
residual	NULL
H,0	NULL
,	NULL
,	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
[	NULL
62	NULL
]	NULL
.	NULL

It	NULL
was	NULL
independent	NULL
of	NULL
Ca®*	NULL
and	NULL
PKC	NULL
and	NULL
was	NULL
prevented	NULL
by	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
have	NULL
been	NULL
recently	NULL
reported	NULL
,	NULL
showing	NULL
172	NULL
V.	NULL
Imbert	NULL
and	NULL
others	NULL
that	NULL
IL-1	NULL
may	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
via	NULL
an	NULL
unknown	NULL
signalling	NULL
mechanism	NULL
that	NULL
excludes	NULL
oxygen	NULL
radicals	NULL
and	NULL
PKC	NULL
activity	NULL
[	NULL
63	NULL
]	NULL
.	NULL

Phosphorylation	NULL
reactions	NULL
have	NULL
been	NULL
proposed	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
inducing	NULL
dissociation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
its	NULL
cytosolic	NULL
inhibitor	NULL
IxB	NULL
[	NULL
51	NULL
]	NULL
,	NULL
but	NULL
to	NULL
date	NULL
no	NULL
direct	NULL
links	NULL
have	NULL
been	NULL
suggested	NULL
between	NULL
tyrosine	NULL
kinases	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
with	NULL
a	NULL
PTPase	NULL
inhibitor	NULL
suggest	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

This	NULL
potential	NULL
role	NULL
is	NULL
currently	NULL
under	NULL
investigation	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

In	NULL
a	NULL
first	NULL
attempt	NULL
to	NULL
define	NULL
more	NULL
clearly	NULL
the	NULL
roles	NULL
played	NULL
by	NULL
different	NULL
cellular	NULL
PTPases	NULL
in	NULL
the	NULL
control	NULL
of	NULL
T-cell	NULL
activation	NULL
events	NULL
,	NULL
we	NULL
made	NULL
use	NULL
of	NULL
CD4S-deficient	NULL
variants	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
variants	NULL
failed	NULL
to	NULL
elicit	NULL
Ca**	NULL
influx	NULL
in	NULL
response	NULL
to	NULL
pervanadate	NULL
.	NULL

Among	NULL
the	NULL
various	NULL
PTPases	NULL
that	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
pervanadate	NULL
,	NULL
CD45	NULL
probably	NULL
plays	NULL
a	NULL
pivotal	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
Ca**	NULL
influx	NULL
during	NULL
cell	NULL
activation	NULL
.	NULL

Inhibition	NULL
of	NULL
CD45	NULL
phosphatase	NULL
activity	NULL
may	NULL
stabilize	NULL
a	NULL
phosphotyrosine	NULL
site	NULL
on	NULL
an	NULL
active	NULL
kinase	NULL
or	NULL
substrate	NULL
which	NULL
act	NULL
as	NULL
positive	NULL
regulators	NULL
of	NULL
Ca	NULL
``	NULL
influx	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
the	NULL
CD4S-negative	NULL
variant	NULL
,	NULL
pervanadate	NULL
failed	NULL
to	NULL
induce	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
cellular	NULL
proteins	NULL
that	NULL
may	NULL
represent	NULL
specific	NULL
CD45	NULL
substrates	NULL
.	NULL

Some	NULL
of	NULL
them	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Ca**	NULL
fluxes	NULL
.	NULL

Together	NULL
,	NULL
the	NULL
data	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
potential	NULL
function	NULL
of	NULL
PTPases	NULL
as	NULL
anti-oncogene	NULL
products	NULL
,	NULL
where	NULL
loss	NULL
of	NULL
a	NULL
PTPase	NULL
gene	NULL
or	NULL
inhibition	NULL
of	NULL
the	NULL
product	NULL
may	NULL
be	NULL
one	NULL
of	NULL
the	NULL
steps	NULL
leading	NULL
to	NULL
malignant	NULL
cell	NULL
transformation	NULL
[	NULL
64,65	NULL
]	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
the	NULL
PTPases	NULL
affected	NULL
by	NULL
pervanadate	NULL
as	NULL
well	NULL
as	NULL
their	NULL
substrates	NULL
is	NULL
likely	NULL
to	NULL
give	NULL
important	NULL
clues	NULL
on	NULL
the	NULL
mechanisms	NULL
regulating	NULL
T-lymphocyte	NULL
activation	NULL
and	NULL
proliferation	NULL
.	NULL

Pervanadate	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
powerful	NULL
pharmacological	NULL
agent	NULL
for	NULL
dissecting	NULL
cellular	NULL
activation	NULL
events	NULL
that	NULL
are	NULL
under	NULL
the	NULL
control	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
INSERM	NULL
)	NULL
,	NULL
by	NULL
a	NULL
grant	NULL
(	NULL
no	NULL
.	NULL

6894	NULL
)	NULL
from	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
(	NULL
ARC	NULL
)	NULL
and	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
Groupement	NULL
des	NULL
Entreprises	NULL
Francaises	NULL
dans	NULL
la	NULL
Lutte	NULL
contre	NULL
Ie	NULL
Cancer	NULL
(	NULL
GEFLUC	NULL
)	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
Jun	NULL
Tsuji	NULL
(	NULL
Nagoya	NULL
University	NULL
,	NULL
Nagoya	NULL
,	NULL
Japan	NULL
)	NULL
for	NULL
kindly	NULL
giving	NULL
c-fos	NULL
plasmid	NULL
,	NULL
to	NULL
Dr.	NULL
Siegmund	NULL
Fischer	NULL
(	NULL
INSERM	NULL
U332	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
for	NULL
generously	NULL
providing	NULL
/ck	NULL
antiserum	NULL
and	NULL
to	NULL
Dr.	NULL
Bernard	NULL
Ferrua	NULL
for	NULL
IL-2	NULL
e.l.i.s.a	NULL
.	NULL

reagents	NULL
.	NULL

We	NULL
thank	NULL
Raymond	NULL
Mescatulo	NULL
for	NULL
illustration	NULL
work	NULL
.	NULL

REFERENCES	NULL
1	NULL
Clevers	NULL
,	NULL
H.	NULL
,	NULL
Alarcon	NULL
,	NULL
B.	NULL
,	NULL
Wileman	NULL
,	NULL
T.	NULL
and	NULL
Tehorst	NULL
,	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
629-662	NULL
2	NULL
-	NULL
Finkel	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Kubo	NULL
,	NULL
R.	NULL
T.	NULL
and	NULL
Cambier	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
12	NULL
,	NULL
79-85	NULL
3	NULL
-	NULL
Hsi	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
Siegel	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Minami	NULL
,	NULL
Y.	NULL
,	NULL
Leuong	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
and	NULL
Sameison	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
10836-10842	NULL
4	NULL
-	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Fletcher	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Sameison	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
1591-1599	NULL
5	NULL
-	NULL
Mustelin	NULL
,	NULL
T.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Isakov	NULL
,	NULL
N.	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
247	NULL
,	NULL
1584-1587	NULL
6	NULL
-	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Fletcher	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Philips	NULL
,	NULL
A.	NULL
F.	NULL
and	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
87	NULL
,	NULL
7722-7726	NULL
7	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
Koretzky	NULL
,	NULL
G.	NULL
,	NULL
Schatzman	NULL
,	NULL
R.	NULL
C.	NULL
and	NULL
Kadlecek	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
88	NULL
,	NULL
5484-5488	NULL
8	NULL
-	NULL
Secrist	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Karnitz	NULL
,	NULL
L.	NULL
and	NULL
Abraham	NULL
,	NULL
R.	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
12135-12139	NULL
9	NULL
-	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161	NULL
,	NULL
446-456	NULL
10	NULL
-	NULL
Veillette	NULL
,	NULL
A.	NULL
,	NULL
Abraham	NULL
,	NULL
N.	NULL
,	NULL
Caron	NULL
,	NULL
L.	NULL
and	NULL
Davidson	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Semin	NULL
.	NULL

Immunol	NULL
.	NULL

3	NULL
,	NULL
143-150	NULL
11	NULL
-	NULL
Cooke	NULL
,	NULL
M.	NULL
P.	NULL
and	NULL
Perlmutter	NULL
,	NULL
P.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
New	NULL
Biol	NULL
.	NULL

1	NULL
,	NULL
66-74	NULL
12	NULL
-	NULL
Sameison	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Philips	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
Luong	NULL
,	NULL
E.	NULL
T.	NULL
and	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
87	NULL
,	NULL
4358-4362	NULL
13	NULL
-	NULL
Tsygankov	NULL
,	NULL
A.	NULL
Y.	NULL
,	NULL
Broker	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Fargnoli	NULL
,	NULL
J.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
18259-18262	NULL
22	NULL
23	NULL
24	NULL
25	NULL
56	NULL
57	NULL
58	NULL
59	NULL
60	NULL
Veillette	NULL
,	NULL
A.	NULL
,	NULL
Bookman	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Horak	NULL
,	NULL
E.	NULL
and	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
301-308	NULL
Rudd	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Trevillyan	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Wong	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
Dasgupta	NULL
,	NULL
J.	NULL
D.	NULL
and	NULL
Schlossman	NULL
,	NULL
S.	NULL
F.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
8§	NULL
,	NULL
5190-5195	NULL
Glaichenhaus	NULL
,	NULL
N.	NULL
,	NULL
Shastri	NULL
,	NULL
N.	NULL
,	NULL
Littman	NULL
,	NULL
D.	NULL
R.	NULL
and	NULL
Turner	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
511-520	NULL
Strauss	NULL
,	NULL
D.	NULL
B.	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
585-593	NULL
Fischer	NULL
,	NULL
E.	NULL
H.	NULL
,	NULL
Charbonneau	NULL
,	NULL
H.	NULL
and	NULL
Tonks	NULL
,	NULL
N.	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
253	NULL
,	NULL
401-406	NULL
Trowbridge	NULL
,	NULL
1	NULL
.	NULL

S.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
23517-23520	NULL
Koretzky	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Picus	NULL
,	NULL
J.	NULL
,	NULL
Thomas	NULL
,	NULL
M.	NULL
L.	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
346	NULL
,	NULL
66-68	NULL
Koretzky	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Picus	NULL
,	NULL
J.	NULL
,	NULL
Schultz	NULL
,	NULL
T.	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
88	NULL
,	NULL
2037-2041	NULL
Peyron	NULL
,	NULL
J.-F.	NULL
,	NULL
Verma	NULL
,	NULL
S.	NULL
,	NULL
de	NULL
Waal	NULL
Malefyt	NULL
,	NULL
R.	NULL
,	NULL
Sancho	NULL
,	NULL
J.	NULL
,	NULL
Terhorst	NULL
,	NULL
C.	NULL
and	NULL
Spits	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Int	NULL
.	NULL

Immunct	NULL
.	NULL

3	NULL
,	NULL
1357-1366	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Tonks	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Fischer	NULL
,	NULL
E.	NULL
H.	NULL
and	NULL
Clark	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Sci	NULL
.	NULL

Acad	NULL
.	NULL

U.S.A.	NULL
85	NULL
,	NULL
8628-8632	NULL
Kiener	NULL
,	NULL
P.	NULL
A.	NULL
and	NULL
Mittler	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
23-28	NULL
Cool	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Tonks	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Charbonneau	NULL
,	NULL
H.	NULL
,	NULL
Walsh	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Fischer	NULL
,	NULL
E.	NULL
H.	NULL
and	NULL
Krebs	NULL
,	NULL
E.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
86	NULL
,	NULL
5257-5261	NULL
Heffetz	NULL
,	NULL
D.	NULL
,	NULL
Bushkin	NULL
,	NULL
1.	NULL
,	NULL
Dror	NULL
,	NULL
R.	NULL
and	NULL
Zick	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
7154-7159	NULL
Pumiglia	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lau	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
Huang	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Burroughs	NULL
,	NULL
S.	NULL
and	NULL
Feinstein	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

286	NULL
,	NULL
441-449	NULL
Trudel	NULL
,	NULL
S.	NULL
,	NULL
Paquet	NULL
,	NULL
M.	NULL
R.	NULL
and	NULL
Grinstein	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

276	NULL
,	NULL
611-619	NULL
Bourgoin	NULL
,	NULL
S.	NULL
and	NULL
Grinstein	NULL
,	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
11908-11916	NULL
Leighton	NULL
,	NULL
B.	NULL
,	NULL
Cooper	NULL
,	NULL
G.	NULL
J.	NULL
S.	NULL
,	NULL
DaCosta	NULL
,	NULL
C.	NULL
and	NULL
Foot	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

276	NULL
,	NULL
289-292	NULL
Fantus	NULL
,	NULL
1	NULL
.	NULL

G.	NULL
,	NULL
Kadota	NULL
,	NULL
S.	NULL
,	NULL
Deragon	NULL
,	NULL
G.	NULL
,	NULL
Foster	NULL
,	NULL
B.	NULL
and	NULL
Posner	NULL
,	NULL
B.	NULL
I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Biochemistry	NULL
28	NULL
,	NULL
8864-8871	NULL
Kadota	NULL
,	NULL
S.	NULL
,	NULL
Fantus	NULL
,	NULL
1	NULL
.	NULL

G.	NULL
,	NULL
Deragon	NULL
,	NULL
G.	NULL
,	NULL
Guyda	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Hersh	NULL
,	NULL
B.	NULL
and	NULL
Posner	NULL
,	NULL
B.	NULL
I	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

147	NULL
,	NULL
259-266	NULL
Mustelin	NULL
,	NULL
T.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.	NULL
M.	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
86	NULL
,	NULL
6302-6306	NULL
Mustelin	NULL
,	NULL
T.	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Oncogene	NULL
5	NULL
,	NULL
809-813	NULL
Mustelin	NULL
,	NULL
T.	NULL
,	NULL
Pessa-Morikawa	NULL
,	NULL
T.	NULL
,	NULL
Autero	NULL
,	NULL
M.	NULL
,	NULL
Gassman	NULL
,	NULL
M.	NULL
,	NULL
Andersson	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
Gahnberg	NULL
,	NULL
C.	NULL
G.	NULL
and	NULL
Burn	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
1173-1178	NULL
Chomczynski	NULL
,	NULL
P.	NULL
and	NULL
Sacchi	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
,	NULL
156-159	NULL
Church	NULL
,	NULL
G.	NULL
and	NULL
Gilbert	NULL
,	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
81	NULL
,	NULL
1991-1995	NULL
Osborn	NULL
,	NULL
I.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
and	NULL
Nabel	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
86	NULL
,	NULL
2236-2240	NULL
Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovits	NULL
,	NULL
R.	NULL
M.	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1479	NULL
Hémar	NULL
,	NULL
A.	NULL
,	NULL
Cereghini	NULL
,	NULL
S.	NULL
,	NULL
Cornet	NULL
,	NULL
V.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Israél	NULL
,	NULL
A.	NULL
,	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
and	NULL
Dautry-Varsat	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
,	NULL
146	NULL
,	NULL
2409-2416	NULL
Ferrua	NULL
,	NULL
B.	NULL
,	NULL
Aussel	NULL
,	NULL
C.	NULL
and	NULL
Fehimann	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
97	NULL
,	NULL
215-221	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
243	NULL
,	NULL
355-361	NULL
Testi	NULL
,	NULL
R.	NULL
,	NULL
Philips	NULL
,	NULL
J.	NULL
H.	NULL
and	NULL
Lanier	NULL
,	NULL
L.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
1854-1860	NULL
Cantrell	NULL
,	NULL
D.	NULL
A.	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Science	NULL
224	NULL
,	NULL
13112-13114	NULL
Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Krdnke	NULL
,	NULL
M.	NULL
,	NULL
Peffer	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Depper	NULL
,	NULL
J.	NULL
M.	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
82	NULL
,	NULL
6281-6286	NULL
Granelli-Piperno	NULL
,	NULL
A.	NULL
and	NULL
Nolan	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
2734-2739	NULL
Hivroz-Burgaud	NULL
,	NULL
C.	NULL
,	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21	NULL
,	NULL
2811-2819	NULL
Kawakami	NULL
,	NULL
K.	NULL
,	NULL
Scheidereit	NULL
,	NULL
C.	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
85	NULL
,	NULL
4700-4704	NULL
Meyer	NULL
,	NULL
R.	NULL
,	NULL
Hatada	NULL
,	NULL
E.	NULL
N.	NULL
,	NULL
Hohmann	NULL
,	NULL
H.-P.	NULL
,	NULL
Haiker	NULL
,	NULL
M.	NULL
,	NULL
Bartsch	NULL
,	NULL
C.	NULL
,	NULL
Réthlisberger	NULL
,	NULL
U.	NULL
,	NULL
Lahm	NULL
,	NULL
H.-W.	NULL
,	NULL
Schlaeger	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
van	NULL
Loon	NULL
,	NULL
A.	NULL
P.	NULL
G.	NULL
M.	NULL
and	NULL
Scheidereit	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
88	NULL
,	NULL
966-970	NULL
Bauerle	NULL
,	NULL
P.	NULL
A.	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
242	NULL
,	NULL
540-546	NULL
Ghosh	NULL
,	NULL
S.	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
344	NULL
,	NULL
678-682	NULL
Baverle	NULL
,	NULL
P.	NULL
A.	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
211-217	NULL
Grinstein	NULL
,	NULL
S.	NULL
,	NULL
Furuya	NULL
,	NULL
W.	NULL
,	NULL
Lu	NULL
,	NULL
D.	NULL
J.	NULL
and	NULL
Mills	NULL
,	NULL
G.	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
318-327	NULL
Heffetz	NULL
,	NULL
D.	NULL
,	NULL
Ruiter	NULL
,	NULL
W.	NULL
J.	NULL
and	NULL
Zick	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

288	NULL
,	NULL
631-635	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
McVicar	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bailey	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Burns	NULL
,	NULL
C.	NULL
and	NULL
Smyth	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
89	NULL
,	NULL
10306-10310	NULL
Garcia-Morales	NULL
,	NULL
P.	NULL
,	NULL
Minami	NULL
,	NULL
Y.	NULL
,	NULL
Luong	NULL
,	NULL
E.	NULL
,	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
and	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
87	NULL
,	NULL
9255-9259	NULL
Deans	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Kanner	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Torres	NULL
,	NULL
R.	NULL
M.	NULL
and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
immunol	NULL
.	NULL

22	NULL
,	NULL
661-668	NULL
Danielian	NULL
,	NULL
S.	NULL
,	NULL
Alcover	NULL
,	NULL
A.	NULL
,	NULL
Polissard	NULL
,	NULL
L.	NULL
,	NULL
Stefanescu	NULL
,	NULL
M.	NULL
,	NULL
Acuto	NULL
,	NULL
0.	NULL
,	NULL
Fischer	NULL
,	NULL
S.	NULL
and	NULL
Fagard	NULL
,	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
2915-2921	NULL
Niklinska	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
Yamada	NULL
,	NULL
H.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
7154-7159	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
Wiscocil	NULL
,	NULL
R.	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

133	NULL
,	NULL
123-128	NULL
Lenardo	NULL
,	NULL
M.	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
227-229	NULL
62	NULL
Schreck	NULL
,	NULL
R.	NULL
,	NULL
Rieber	NULL
,	NULL
P.	NULL
and	NULL
Bauerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
2247-2258	NULL
63	NULL
-	NULL
Stylianou	NULL
,	NULL
E.	NULL
,	NULL
O'Neill	NULL
,	NULL
L.	NULL
A.	NULL
J.	NULL
,	NULL
Rawlinson	NULL
,	NULL
L.	NULL
,	NULL
Edbrooke	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Woo	NULL
,	NULL
P.	NULL
and	NULL
Saklatvala	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
15836-15841	NULL
64	NULL
-	NULL
Klarlund	NULL
,	NULL
J.	NULL
K.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
41	NULL
,	NULL
707-717	NULL
Received	NULL
19	NULL
February	NULL
1993/10	NULL
August	NULL
1993	NULL
;	NULL
accepted	NULL
17	NULL
August	NULL
1993	NULL
Regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
by	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
173	NULL
65	NULL
-	NULL
Laforgia	NULL
,	NULL
S.	NULL
,	NULL
Morse	NULL
,	NULL
B.	NULL
,	NULL
Levy	NULL
,	NULL
J.	NULL
,	NULL
Barnea	NULL
,	NULL
G.	NULL
,	NULL
Cannizaro	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Li	NULL
,	NULL
F.	NULL
,	NULL
Nowell	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
Boghosian-Seil	NULL
,	NULL
L.	NULL
,	NULL
Glick	NULL
,	NULL
J.	NULL
,	NULL
Weston	NULL
,	NULL
A.	NULL
,	NULL
Harris	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Drabkin	NULL
,	NULL
H.	NULL
,	NULL
Patterson	NULL
,	NULL
D.	NULL
,	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Schlessinger	NULL
,	NULL
J.	NULL
and	NULL
Huebner	NULL
,	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
88	NULL
,	NULL
5036-5040	NULL

